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AR androgen receptor  
Ara-C 1--darabino-furanosyl cytosine 
bp base pair 
BPE bovine pituitary extract 
BPH benign prostatic hyperplasia  
BrdU 5-bromo-29-deoxyuridine 
cDNA complementary deoxyribonucleic acid 
COX5B cytochrome c oxidase subunit Vb 
DAXX death-domain associated protein 
DHT dihydrotestosterone 
ELISA enzyme-linked immunosorbent assay 
ER estrogen receptor 
FBS fetal bovine serum 
FHL2 four and a half LIM domains 2 
FI fluorescence intensity 
FL full-length 
FLNA filamin A, alpha 
GRIP1 GR-interacting protein 1 
h hour 
HVEM herpesvirus entry mediator 
IGF insulin-like growth factor  
JNK c-Jun N-terminal kinase 
LIGHT homologous to lymphotoxins, shows inducible expression, and competes with 
herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T 
lymphocytes 
LOH loss of heterozygosity  
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LT lymphotoxin 
LTR lymphotoxin-beta receptor 
mAb monoclonal antibody 
min minute 
MMTV mouse mammary tumor virus 
mRNA messenger ribonucleic acid 
M2H mammalian two- hybrid 
NCOA1 nuclear receptor coactivator 1 
NFB nuclear factor kappa B  
PAK6 p21protein-activated kinase 6  
PBS phosphate-buffered saline 
PIAS1 protein inhibitor of activated STAT, 1  
PIAS3 protein inhibitor of activated STAT, 3 
PIAS4 protein inhibitor of activated STAT, 4 
PNRC proline-rich nuclear receptor coactivator 2  
PrECs prostate epithelial cells  
PSA prostate-specific antigen 
RLU relative light unit 
RMS rhabdomyosarcoma 
rRNA ribosomal ribonucleic acid 
RT-PCR reverse transcription polymerase chain reaction 
SARM(s） selective androgen receptor modulator(s） 
SEAP secreted alkaline phosphatase 
S.E.M standard error of mean 
SENP1 SUMO1/sentrin specific peptidase 1 
SERM elective estrogen receptor modulator  
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SkMCs skeletal muscle cells  
SM smooth muscle 
TAF1 TAF1 RNA polymerase II, TATA box binding protein associated factor, 250kDa 
TEF-1 transcriptional enhancer factor -1  
TNF tumor necrosis factor 
TNFR TNF receptor  
TPA 12-o-tetracanoylphorbol-13-acetate 
Ts testosterone 
rRNA ribosomal ribonucleic acid 
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Abstract  
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Cell signaling is a kind of molecular mechanisms to transmit extracellular stimuli to 
intracellular machineries. It is also known as signal transduction and includes cellular responses to 
hormones, cytokines, neuro transmitters, and autacoids via corresponding receptors and they elicit a 
variety of biological responses. Transcriptional activity-mediated signaling is one of major 
components of cell signaling. It alters or modifies cellular functions through induction or 
suppression of gene expression and its disruption or dysfunction causes various diseases including 
cancers. Therefore, the understanding of cell signaling has attracted the interest of many researchers 
in biomedical field. In this study, I have studied on the signal transduction mechanisms of tumor 
necrosis factor (TNF) receptor and androgen receptor (AR); and explored novel target molecules for 
anticancer agents. 
In the first part, I have studied on the cell signaling which relates with the effect of LIGHT on 
human rhabdomyosarcoma cell line RD. LIGHT is a member of the TNF superfamily, which plays 
multiple roles in the development of immune system, and its receptors have been identified to be 
lymphotoxin (LT)  receptor (LTR) and the herpesvirus entry mediator (HVEM)/TR2. TNF is 
known to induce two distinct signaling pathways, apoptosis via caspase activation and nuclear 
factor kappa B (NFB) activation. LIGHT decreased the number of viable RD cells, modulated cell 
cycle distribution, induced clear morphological change with concomitant expression of smooth 
muscle (SM) -actin mRNA, and stimulated NFB-dependent transcriptional activity and 
chemokine production. LT12, another TNF family ligand for LTR, had similar effects on RD 
cells but TNF and LT did not. These results indicate that LIGHT suppresses growth of RD cells 
and induces transformation into smooth muscle through LTR. 
In the second part, I have studied on the cell signaling which underlie tissue selectivity of 
TSAA-291, a steroidal antiandrogen which was previously used for benign prostatic hyperplasia 
(BPH) treatment. AR is a member of the nuclear hormone receptor superfamily that is activated by 
binding with either of endogenous androgens, testosterone (Ts), or dihydrotestosterone (DHT). It 
elicits diverse range of biological changes and its signaling is also involved in the development of 
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tumors in prostate and some other tissues. Selective androgen receptor modulator (SARM) is a class 
of AR ligands that specifically bind to AR and display either agonistic or antagonistic effects 
depending on target organs. I have identified that TSAA-291 exhibited partial AR agonist activity 
in in vitro reporter assay and in vivo pharmacological studies. Daily administration of TSAA-291 
increased the weight of levator ani muscle without increasing the weight of the prostate and seminal 
vesicle in castrated mice. Comprehensive cofactor recruitment analysis of AR using TSAA-291 and 
endogenous AR ligands clarified that 12 of 112 cofactors including the protein inhibitor of activated 
STAT, one (PIAS1) were differently recruited to AR in the presence of TSAA-291 or endogenous 
androgens. These results indicate that TSAA-291 has a tissue-specific effect, as characteristic of 
SARM. Moreover, my comprehensive analysis suggested that binding with ligand induces specific 
conformation changes of AR, which modulates its surface topology and protein-protein interaction 
with cofactors, such as PIAS1, and leads to tissue-specific transcriptional gene regulation. 
Based on two studies, I propose that LIGHT and SARM(TSAA-291）can lead to a novel and 
feasible therapeutic approach for rhabdomyosarcoma or hormone-related disease including cancer. 
These would be typical example for the application of basic studies on the transcriptional 
activity-mediated signaling to drug discovery. 
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As a part of mechanisms to maintain homeostasis of life, cells receive and respond to inputs 
from their environment, such as nutrients, osmotic pressure, humoral factors, extracellular matrices 
and cell-cell contacts. They are integrated or coordinated to regulate a variety of cellular 
phenomena, such as gene expression, protein synthesis, metabolism, proliferation, morphogenesis, 
differentiation and programmed cell death (Martin, 2003; Dangsheng, 2012). Cell signaling is a 
cellular mechanism to receive, amplify and transmit external input at cell membrane, cytoplasm, or 
nucleus. In that sense, cell signaling is also referred to as signal transduction. Molecular component 
of this process include various type of proteins, such as receptors, enzymes, transcriptional factors, 
transporters and structural proteins. Regardless of the nature of initiating signal, the selectivity of 
cellular responses is primarily determined by the receptors which recognize corresponding signaling 
molecules so called ligands. On the other hand, molecular events downstream of receptors overlap 
each other. Therefore, it is still incompletely understood how the cells direct the traffic of highly 
complicated signaling to exert precisely controlled vital phenomena. It is well established that 
dysregulation of cell signaling causes many diseases such as cancer (Martin, 2003). In that sense, 
understanding of cell signaling mechanism under various disease states would offer important 
information for the development of novel therapeutic strategies. Among numerous signaling 
pathways of cells, I focused attention to tumor necrosis factor (TNF) receptor and androgen 
receptor (AR) signaling which are involved in tumorigenesis or severe cancer-related symptoms. 
The direct relationship or crosstalk between TNF and AR signaling is still controversial, however, it 
is suggested that androgen actions on TNF-induced signaling pathways. TNF binding to trimeric 
TNFR1 leads to assembly of complex I, which then results in activation of nuclear factor kappa B 
(NF-κB), c-Jun N-terminal kinase (JNK), and/or the caspase cascade, depending on cellular context. 
All of these three TNF downstream signaling pathways can be regulated by androgen (Bosscher 
KD et al., 2006). 
Members of the TNF superfamily, including original TNF ligands, play important roles in cell 
activation, proliferation, differentiation, apoptosis, immunoglobulin class switch, immune evasion, 
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and immune suppression (Smith et al., 1994; Aggarwal and Natarajan, 1996; Baker and Reddy, 
1996; Locksley et al., 2001). They exert their biological functions via interaction with 
transmembrane receptors, comprising the TNF receptor family. Ligand-receptor binding causes a 
conformational change in the receptor, which triggers subsequent signaling cascade (Purves et al., 
2001). LIGHT is a member of the TNF ligand superfamily and it was first identified from database 
based on structural similarity (Hikichi et al., Patent No. US6235878). It contains 240 amino acids 
with an N-terminal cytosolic domain of 37 residues that precedes a stretch of 22 hydrophobic 
residues characteristic of a type II transmembrane protein (Mauri et al., 1998; Figure 1A). LIGHT 
showed 20%-30% structural identity to the other TNF ligands including FasL and TNF (Mauri et 
al., 1998; Figure 1B). LIGHT binds two known as TNF receptor family, lymphotoxin (LT)- 
receptor (LTR) and the herpesvirus entry mediator (HVEM)/TR2 (Mauri et al., 1998; Crowe et al., 
1994). As previous various studies have shown, LIGHT played a role in the immune modulation 
(Zhai et al., 1998; Celik et al., 2009) and had a potential value in breast and colorectal cancer 
therapy (Zhai et al., 1998; Harrop et al., 1998). Furthermore, it is known that LIGHT stimulated 
NF-B transcriptional activity in the human primary hepatocytes and inhibits the apoptotic caspase 
cascade induced by TNFMatsui et al., 2002; Figure 1C. Rhabdomyosarcoma (RMS) is the most 
common soft tissue sarcoma in children originating from immature cells and it has a long-term 
survival rate in children of only 50%-70% (Parham 1994; Pappo et al., 1995), and no standard 
treatment for adults with recurrent/refractory RMS has yet been established (Sasada et al., 2016). 
As shown in part I of this thesis, I have identified that LIGHT, a member of the TNF superfamily, 
induces morphological changes and delays proliferation in the human RMS cell line RD (Hikichi et 
al., 2001). Since LIGHT is a pleiotropic molecule initiating diverse biological functions depending 
on the receptor expression profiles of the target cells, understanding mechanism underlying 
LIGHT-mediated anti-tumor activity is valuable for discovering a novel therapeutic strategy for 
RMS. 
Another key signal pathway of my interest is AR signaling. Androgen is all-inclusive term for 
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group of hormones that play a role in male traits and reproductive activity. Testosterone (Ts) and 
dihydrotestosterone (DHT), the major endogenous ligands for AR, are involved in a variety of 
physiologic functions in human such as maintaining sexual function, germ cell development, fat 
distribution, maintenance of muscle mass/strength, and central nervous systems. It has been known 
that androgen deficiency in elder men is the most prevalent disorder of AR signaling (Bhasin et al., 
2006). Age-associated loss of muscle mass/strength and physical functional limitation increases a 
risk of many chronic illnesses, such as chronic obstructive lung disease, congestive heart failure, 
and cancer cachexia (Bassey et al,, 1992; Baumgartner et al., 1999; Baumgartner et al., 2000; 
Melton et al., 2000; Roy et al,, 2002; Srinath and Dobs, 2014). These symptoms may improve with 
Ts treatment, but various adverse effects such as prostate or latent prostate cancer would associate it 
(Gooren, 2003). To overcome these problems of Ts, alternate and promising candidates for anabolic 
therapies have long been explored. Recently, it was revealed that existing therapeutic agents such as 
selective androgen receptor modulator (SARM) have a function to promote anabolic therapies 
(Bhasin et al., 2006; Narayanan et al., 2008; Negro-Vilar 1999). SARM is a class of AR ligands that 
bind AR and is known to display tissue-selective activation of androgenic signaling (Bhasin et al., 
2006; Narayanan et al., 2008). SARM can exert anabolic effects on the skeletal muscle and bone 
without dose-limiting and Ts-like adverse effects. Furthermore, SARM has an anti-tumor activity, 
especially on hormone-related cancer (Narayanan et al., 2014; Chisamore et al., 2016). Taken 
together, there is an enormous promise for anabolic therapies with SARM that can improve physical 
function and achieve anticancer effect without any adverse events. 
While the physiological action and anticancer effect of SARM have been clarified, an 
underlying mechanism for its tissue selectivity is still controversial. Narayanan et al. (2008) 
reported that SARM and endogenous androgens activate several distinct signal pathways. But the 
reason why only SARM is able to show tissue-specific transcriptional regulation and selective 
biological effect remains unclear. I hypothesized that the tissue selectivity of SARM might be 
achieved by SARM-specific patterns of cofactor recruitment to AR. To confirm my hypothesis, I 
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have constructed a comprehensive mammalian two-hybrid (M2H) system with full-length (FL) 
human AR and a total of 112 cofactors in 293T cells. With this system, I have assessed the effects 
of SARM and endogenous androgens on the pattern of cofactor recruitment to AR (Figure 2). As 
shown in part II of this thesis, it was revealed for the first time that PIAS1 is key cofactor to explain 
the tissue selectivity of SARM (Hikichi et al., 2015). 
Here I summarize my findings on the cell signaling of extracellular and intracellular 
receptor-ligand mediated systems. In part I, I have discovered that LIGHT suppresses growth and 
induces transformation of RD cancer cells into smooth muscle cells. In part II, I have clarified that 
TSAA-291, used for BPH treatment, is SARM and suggest that TSAA-291 may induce different 
conformational changes of the AR. Its profile in cofactor recruitment, such as PIAS1, supports 
tissue-specific activity of TSAA-291. Further studies targeting LIGHT and SARM are expected to 
lead discovery of effective medicines for cancer or hormone-related disease.  
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Figures 
 
Figure 1. Conceptual diagram and the sequence of LIGHT and alignment with TNF 
Superfamily (A) Sequence of LIGHT. Amino-acid sequence deduced from the cDNA sequence. 
The asterisk (*) indicates the position of the predicted N-glycosylation site. (B) Alignment of 
LIGHT with TNF-related ligands. Sequences were aligned with ClustalW (Pam250 matrix) 
(Macvector). This alignment excludes ligands for CD27, CD30, and Ox-40. The asterisks (*), the 
contact residues in LT for TNFR60; bars, the -strands that form the scaffold in LT as 
designated by convention. Homology regions are boxed with identical residues shaded. 
(C) Schematic illustration for relationship between TNFligands and their receptors showed the 
known interactions between members of TNF ligand family and TNF receptor family, and adaptor 
proteins and signaling pathways associated with those receptors. 
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Figure 2. Conceptual diagram to identify key cofactors using M2H systems The tissue 
selectivity of SARM is the result of the different patterns of cofactor recruitment to AR induced by 
ligands. The cofactors that show significant different profiles between SARM and endogenous 
androgens were selected by comprehensive M2H systems. 
  
 17 
 
 
 
 
Endogenous androgens（DHT）  
 
 
 
 
 
SARM（TSAA-291） 
 
 
 
Figure 2  
GAL4 binding site Luciferase
GAL4
AR cofactor
VP16
DHT
+++++
recruit
VP16
cofactor
GAL4 binding site Luciferase
GAL4
SARM
（TSAA-291）
+
VP16
cofactorrecruit
 18 
 
 
 
 
 
 
 
 
Part I 
LIGHT, a Member of the TNF Superfamily, Induces Morphological Changes and Delays 
Proliferation in the Human Rhabdomyosarcoma Cell Line RD 
  
 19 
 
Abstract 
 
LIGHT is a member of the TNF superfamily, which binds two known receptors, LTR and 
HVEM/TR2. I investigated the effects of LIGHT on the RMS cell line RD. LIGHT delayed cell 
proliferation and induced morphological changes of the cells. These effects were not shown by 
other TNF family ligands such as TNF and LT, which induced the transcriptional activity of 
NF-B and NF-B-responsible chemokine productions in the same manner as did LIGHT. LT12, 
another TNF family ligand for LTR, was shown to have similar activities in RD cells as LIGHT. 
Both LIGHT and LT12 induced the expression of muscle-specific genes such as smooth muscle 
(SM) -actin, while TNF and LT did not. These findings indicate that LIGHT may be a novel 
inducer of RD cell differentiation associated with SM -actin expression through the LTR. 
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Introduction 
 
RMS is the most common soft tissue sarcoma in children originating from immature cells and 
it has a long-term survival rate in children of only 50-70% (Pappo et al., 1995; Parham, 1994). 
These tumors resemble primitive skeletal muscle-forming cells in appearance and are highly 
aggressive, suggesting that RMS may arise from skeletal muscle cells that are arrested along the 
normal myogenic pathway to maturation (Pappo et al., 1995; Parham, 1994). Several studies of the 
molecular basis in RMS have shown RMS to be associated with loss of heterozygosity (LOH) at the 
11p15 locus, which effects the expression of insulin-like growth factor (IGF), which is a growth 
factor of RMS (Scrable et al., 1987; El-Badry et al., 1990). RMS is characterized by the expression 
of several muscle-specific markers such as myogenic-promoting transcription factor MyoD. 
Although the expression of such factors typically correlates with myogenic differentiation, RMS 
fails to undergo terminal differentiation into skeletal muscle (Parham, 1994). Members of the TNF 
family play important roles in cell activation, proliferation, differentiation, apoptosis, 
immunoglobulin class switch, immune evasion, and immune suppression (Smith et al., 1994; 
Aggarwal and Natarajan., 1996; Baker and Reddy., 1996; Locksley et al., 2001). Recently, a new 
member of the TNF family, designated as LIGHT, was identified as a cellular ligand for both 
HVEM, also designated as TR2, and LTR (Zhai et al., 1998; Mauri et al., 1998; Tamada et al., 
2000; Rooney et al., 2000). LIGHT mRNA is highly expressed in splenocytes, activated PBL, CD8+ 
tumor-infiltrating lymphocytes, granulocytes, and monocytes but not in the thymus or the tumor 
cells examined to date (Zhai et al., 1998). LTR is prominent on epithelial cells but absent in T and 
B lymphocytes (Crowe et al., 1994); it is also involved in the development of peripheral lymph 
nodes and spleen architecture (Ettinger et al., 1996; Koni et al., 1997). LTR is the receptor for 
LIGHT as well as membrane-bound LT12 trimers (Mauri et al., 1998; Crowe et al., 1994), and 
HVEM/TR2 has been shown to be the receptor for LIGHT, LT, and herpes simplex virus envelope 
glycoprotein D (Kwon et al., 1997; Marsters et al., 1997). Recently, LIGHT was reported to be able 
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to induce apoptosis in several tumor cells (Zhai et al., 1998), and has a CD28-independent 
costimulatory activity leading to T-cell growth and differentiation (Tamada et al., 2000). Thus, 
LIGHT is a pleiotropic molecule initiating diverse biological functions depending on the receptor 
expression profiles of the target cells. I found that LIGHT delayed cell proliferation and induced 
morphological changes in a human RMS cell line, RD, associated with the expression of smooth 
muscle (SM) -actin mRNA. LT12, another TNF family ligand for LTR, had similar effects on 
RD cells, but TNF and LT did not. Therefore, LIGHT may be a novel inducer of morphological 
changes on RMS by expressing cytoskeletal protein(s) through LTR.  
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Material and Methods 
 
Materials and cell culture 
Human RMS cell line RD was purchased from the American Type Culture Collection 
(Rockville, MD). The cells were maintained in DMEM containing 10% FBS and 1 mM sodium 
pyruvate. Recombinant human TNF, LT, and LT12 were purchased from R&D Systems 
(Abingdon, UK). TPA was purchased from Wako Pure Chemical Industries (Osaka, Japan). 
RANTES and IL-8 productions were measured using Quantikine kits (R&D Systems). Soluble 
LIGHT proteins were produced and purified as follows: a FL human LIGHT cDNA was obtained 
from a SUPERSCRIPT human liver cDNA library (Gibco-BRL, MD) using the GENETRAPPER 
cloning system (Gibco-BRL) with the following probes and colony-PCR primers: 
5'-AGGTCAACCCAGCAGCGCATCTCA-3' and 5'-CACCATCACCCACGGCCTCTACAAG-3', 
for cDNA cloning, 5'-AGGTCAACCCAGCAGCGCATCTCACAGG-3' and 
5'-CAAATTAAACCGGGTACCATCACGCAGTCG-3', for colony-PCR. The extracellular region 
(encoding Ile84 to Val240) of LIGHT was amplified from the cDNA by PCR using the following 
primers: 5'-GAATTCGATACAAGAGCGAAGGTCTCACGAGGTC-3' and  
5'-AAATCTAGATCCTTCCTTCACACCATGAAAGCCCC-3'. The PCR product was digested 
with EcoRI and XbaI, and ligated into the EcoRI–XbaI site of pFLAG-CMV-1 expression vector 
(Eastman Chemical Company, NY). The preprotrypsin-FLAG-LIGHT DNA region in the vector 
was further digested with SacI and XbaI, and ligated into the SacI–XbaI site of pFAST-BAC1 
vector (Gibco-BRL). The plasmid was infected into SF9 insect cells to generate the recombinant 
LIGHT proteins according to the procedure of Bac-to-Bac Baculovirus Expression System 
(Gibco-BRL). The FLAG-tagged soluble LIGHT proteins were purified with an anti-FLAG mAb 
affinity column, ANTI-FLAG M2-Agarose (Sigma, MO). 
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Semiquantitative RT-PCR analysis 
Semiquantitative PCR amplification using primers for either human SM -actin mRNA 
(5'-GCTCACGGAGGCACCCCTGAA-3' and 5'-CTGATAGGACATTGTTAGCAT-3'), human 
-actin mRNA (5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' and 
5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3'), human myogenin mRNA 
(5'-CCGTGGGCGTGTAAGGTGTG-3' and 5'-ACGATGGAGGTGAGGGAGTGC-3'), 
or human Id-1 mRNA (5'-CGAGGTGGTGCGCTGTCTGTCT-3' and 
5'-TCGCCGTTGAGGGTGCTGAG-3') was performed using the Advantage 2 PCR Enzyme 
Systems (Clontech, CA) to amplify the 591-bp fragment for SM -actin cDNA, 540-bp fragment 
for -actin cDNA, 416-bp fragment for myogenin cDNA, or 315 bp fragment for Id-1 cDNA, 
respectively. I used 18S rRNA cDNA detection as an internal control. 
 
Cell proliferation assay 
Cell proliferation assays were performed using the cell proliferation ELISA, BrdU kit (Roche, 
NY). Briefly, after the RD cells (2500 cells/well) were cultured in 96-well plates with each ligand 
for 4 days, the cells were labeled by adding BrdU solution for 1.5 h (final concentration of 10 mM), 
before being washed and fixed. The cells were treated with an anti-BrdU-POD antibody for 1.5 h. 
After washing, the cells were treated with POD substrate solution and the absorbance at 450 nm/690 
nm was measured with a plate reader. In a separate procedure, the RD cells were plated in duplicate 
in 25 cm2 flasks with each ligand for 6 days. The living cell number was determined using the 
trypan blue exclusion method. 
 
Flow cytometry 
RD cells (1 × 106 cells) were cultured with or without LIGHT for 72 h, fixed in 70% ethanol 
for 24 h at -20°C, and washed with PBS. The cells were incubated with 2 mg/ml RNaseA for 20 
min at 37°C, and stained with propidium iodide for 30 min at room temperature. The DNA content 
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of the cells was determined using a flow cytometry FACScan (Becton–Dickinson, Germany). 
 
NF-B transcriptional activity assay 
The NF-B transcriptional activity was determined using a Mercury Pathway Profiling 
System (Clontech). Briefly, RD cells (1 × 106 cells) were seeded in a 12-well plate for 1 day and 
were then transfected with 0.5 mg pNF-B-SEAP vector using 1.5 ml FuGENE6 reagent (Roche) 
for 20 h. After the cells were exposed with or without each ligand for the indicated times, the SEAP 
activity in the culture media was determined using a Great EscAPe chemiluminescence detection kit 
(Clontech). 
 
Western blot and immunocytochemistry 
Western blot analysis was performed using a ProtoBlotII AP System (Promega, Germany). 
Briefly, the RD cells (7 × 104 cells) were cultured with reagents for 6 days and lysed with a high 
salt buffer (0.6 M KCl in 10 mM Tris, pH 7.5, and protease inhibitors). The soluble proteins 
collected by centrifugation from the lysates were separated by 2-15% SDS-polyacrylamide gels, 
and then transferred onto nitrocellulose membranes. The membranes were then incubated with a 
mouse anti-skeletal myosin monoclonal antibody (mAb) MY-32 (Zymed, CA) at 1:100 dilutions for 
1 h at room temperature. After washing, the blots were incubated for 1 h with an anti-mouse IgG (H 
+ L) AP Conjugate (Promega) at 1:5000 dilutions before being exposed to the substrate solution. 
For immunocytochemistry, the RD cells (6 × 103 cells) were cultured with various reagents for 6 
days and then fixed in ethanol:acetone (1:1) for 30 min at 220°C before being blocked with PBS 
containing 1% BSA. The cells were then incubated with MY-32 mAb for 1 h, following 
HRP-anti-mouse IgG F(ab)'2 (ICN/Cappel, OH) as the 2nd antibody against MY-32 mAbs. 
After washing, diaminobenzidine (Sigma, MO) was used as a peroxidase substrate to visualize the 
stained cells. 
  
 25 
 
Results 
 
Growth Delay Induced by LIGHT 
As shown in Figure 3A, I found that LIGHT at a concentration above 6 ng/ml had a 
substantial growth inhibitory effect on a human embryonal RMS cell line RD. Though LIGHT 
inhibited the total viable RD cell number by up to about one-third during the first 6 days compared 
with the control growth (Figure 3B), re-exposure of the cells with an excess amount of LIGHT (up 
to 50 ng/ml) did not result in complete suppression of growth. Furthermore, when the cell cycle 
distribution of the LIGHT-treated cells was compared with that of control cells by flow cytometry, 
the G0/G1 percentage of the cells increased only slightly, from 49 to 60%, even after 6 days of 
treatment (Figure 3C). Therefore, the effect of LIGHT on the RD cells seemed to involve a delay of 
cell proliferation rather than a frank arrest of the growth. A similar inhibitory effect was observed 
with LT LT12, while the other TNF family ligands, such as TNF and LT, had only a weak 
suppressive effect on RD cell proliferation (20% inhibition according to the trypan blue exclusion 
method) (Figure 3B). Interestingly, LT synergistically stimulated the inhibitory effect of LT12, 
as shown in Figure 3. 
 
Morphological Changes Caused by LIGHT 
Observations with phase-contrast microscopy showed that the first 2 days of treatment with 
50 ng/ml of LIGHT induced no morphological changes in the RD cells compared with control cells 
(Figure 4A). After the 5th day of culture, however, more than half of the cells treated with LIGHT 
showed an evident increase in elongated cytoplasm hypertrophy and formed multinucleated 
myotube-like cells (Figure 4B). Cells treated with LT12 showed similar morphological changes 
to those treated with LIGHT (Figure 4C). LT synergistically promoted the changes induced by 
LT12, whereas LT alone did not (Figure 4D, E). As shown in Figure 4F, TPA, a known inducer 
of RD cell differentiation (Aguanno et al., 1990; Bouche et al., 1993), induced a different 
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morphology that seen in the control or LIGHT-treated cells. This suggests that LIGHT causes a 
qualitatively different induction of changes in the morphology of RD cells than does TPA. 
 
NF-B Activation and Chemokine Productions 
To examine whether LIGHT regulates the transcriptional activity of NF-B in the manner of 
other ligands, I monitored the capacity of each ligand that induced the expression of representative 
NF-B-responsive proteins, such as IL-8 or RANTES in RD cells. As shown in Figure 5, all ligands 
induced comparative biological responses including IL-8 and RANTES productions in the cells 
cultured for 3 days. The productivity of each chemokine by LIGHT was similar to that by LT12. 
Further experiments were performed to determine whether this responsiveness was related to the 
transcriptional activity of NF-B. I used a SEAP reporter gene construct driven by four tandem 
copies of Kappa () enhancer element (B4;8) as an NF-B responsive sequence in the Mercury 
Pathway Profiling Systems (Clontech), as described in materials and methods, and found that all 
ligands induced comparative levels of SEAP in RD cells. By contrast, the activity of NF-B 
induced by LIGHT was weaker than that induced by other ligands (Figure 6). Thus, even though 
engagement of TNF or LT induces normal transcriptional activity of NF-B in RD cells, the 
activated NF-B was not able to transactivate the growth delay or morphological conversions of RD 
cells. 
 
Induction of Smooth Muscle -Actin Gene Expression 
To investigate possible roles of LIGHT in regulating morphological changes of RD cells, I 
examined apparent alterations of muscle regulatory genes and their protein products. By 
semiquantitative RT-PCR, I analyzed the accumulation of muscle-specific gene transcripts such as 
SM -actin, myogenin, and Id-1. LIGHT and LT12 induced expression of SM -actin mRNA, 
whereas other ligands such as TNF or LT did not. The expression of -actin, myogenin, and Id-1 
were not changed in LIGHT-treated RD cells (Figure 7). It has been reported that RD cells treated 
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with TPA increase their expression of cytoskeletal proteins such as skeletal muscle myosin and 
skeletal muscle -actin, increase their binding of 125I--bungarotoxin, and increase the 
phosphorylation of several proteins including -PKC (Aguanno et al., 1990; Bouche et al., 1993). 
While TPA did not modify the expression of SM -actin or myogenin in the present study, it 
induced skeletal myosin expression in RD cells according to a combined analysis using both 
immunocytochemistry (Figure 8A) and Western blot analysis (Figure 8B) with an anti-skeletal 
muscle myosin mAb MY-32. Conversely, no positive cells or skeletal myosin proteins were found 
in RD cells treated with LIGHT according to this analysis (Figure 8A, B). Immunocytochemistry 
and Western blot analysis using an anti-smooth muscle myosin heavy chain mAb F126.16D9 
(Biocytex, France) showed that none of the ligands tested changed the expression level of smooth 
muscle myosin proteins (data not shown). 
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Discussion 
 
LIGHT is a member of the TNF superfamily, which binds two known receptors, LTR and 
HVEM/TR2. My results indicated that LIGHT plays an important role in the differentiation process 
of human RMS cell line RD. LIGHT caused a marked morphological change in the RD cells 
characterized by growth delay with elongated cytoplasm hypertrophy (Figures 3 and 4) and 
increased SM -actin expression (Figure 7). Furthermore, my results demonstrated that such 
changes in the RD cells are not caused by TNF or LT, except for LT12, which is another TNF 
family ligand specifically bound to LTR. Both TNF and LT stimulated the activation of NF-B 
and the production of NF-B-responsive chemokine in the manner of both LIGHT and LT12, 
indicating that LTR signaling may directly activate differentiation pathways in RD cells (Figures 5 
and 6).  
RD is an embryonal RMS resembling normal fetal skeletal muscle in morphology and it 
expresses several muscle-specific genes such as the myogenic-promoting transcription factor MyoD. 
RD cells are capable of only a limited and abortive spontaneous myogenic differentiation, probably 
because they lack functional p53 (Germani et al., 1994) and have homozygous gene deletion of 
p16ink4 gene (Urashima et al., 1999). Recent evidence suggests that transfection with a 
temperature-sensitive p16 mutant (E119G) gene in RD cells, under a permissive culture condition, 
reduced CDK6-associated kinase activity, induced G1 growth arrest, and induced morphological 
change coupled with the expression of myogenin and myosin light chain genes (Urashima et al., 
1999). However, Knudsen et al. (1998) reported that ectopic expression of p21cip1, p16ink4, or 
p27kip1 in RD cells caused the cell growth arrest, but not detectable expression of myogenic 
markers such as myosin heavy chain, indicating that these activities alone are not sufficient for RD 
cells to differentiate. In any case, the failure of RMS to undergo terminal differentiation into 
skeletal muscle may be one mechanism by which these cells gain the growth advantage necessary 
for tumor formation. While the growth inhibitory effect of LIGHT on RD cells was obvious at a 
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concentration of 6 ng/ml (Figure 3A), at 50 ng/ml LIGHT, which is an excessive amount, the 
inhibition increased only marginally, suppressing the cell number by one-third compared with the 
control (Figure 3B). When I compared the cell cycle distribution in LIGHT-treated cells with that 
for control cells, the G0/G1 phase percentage was only slightly increased, from 49% to 60% (Figure 
3C). The flow cytometry analysis was performed after excluding the differentiated cells with 
elongated cytoplasm hypertrophy and multinucleated myotube-like cells. Thus, there may be the 
possibility that the differentiated cells preferentially arrest cell growth in the culture system. 
Therefore, the reduction in cell number by LIGHT may be due to morphological conversion of part 
of the RD cells rather than a typical growth arrest or cytotoxicity. Since I did not investigate the 
growth characteristics of the morphologically changed cells, more experiments are needed to better 
understand these phenomena.  
TPA is known to be a differentiation reagent of RD cells accompanied with inducible 
expression of muscle-specific genes such as skeletal muscle -actin and myosin light chain genes. 
Both LIGHT- and LT12-treated RD cells markedly expressed SM -actin gene (Figure 7), but 
TPA did not. By contrast, TPA slightly reduced the expression of Id-1 mRNA, a negative regulator 
of MyoD, but LIGHT and LT12 did not (Figure 7). Conversely, skeletal myosin expression was 
increased in TPA-treated RD cells, but not in those treated by LIGHT or LT12 (Figure 8). These 
results suggest that the differentiation state induced by LIGHT and LT12 is completely different 
from that induced by TPA. The SM -actin gene is well-known to be activated during the early 
stage of embryonic cardiovascular development, switched off in late stage heart tissue, and replaced 
by cardiac and skeletal -actins. It also appears during vascular development, and becomes the 
most abundant protein in adult vascular smooth muscle cells. Tissue-specific expression of SM  
-actin is required for the principal force-generating capacity of the vascular smooth muscle cells. 
Therefore, LIGHT might activate the transcriptional machinery necessary for transdifferentiation 
from a skeletal- to a smooth-muscle lineage through LTR. 
Signaling by TNF family members is initiated by an aggregation of specific cell surface 
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receptors. TNF, LT, LT12, and LIGHT exhibit distinct but overlapping patterns of binding to 
four cognate receptors: TNF receptor type 1 (TNFR1), TNF receptor type 2 (TNFR2), LTR, and 
HVEM/TR2, which together define a core group within the larger TNF superfamily. TNF binds 
two receptors, TNFR1 and TNFR2, and LT binds TNFR1, TNFR2, and HVEM/TR2. LT12, 
predominantly expresses in activated T cells and specifically binds LTR. Although LIGHT binds 
both LTR and HVEM/TR2, the cross-utilization of the receptors suggests functional redundancy 
of the ligand. When I examined the expression levels of these four receptors via RT-PCR, I 
observed that they all expressed in the cells. However, the expression level of each receptor mRNA 
was quite different; the lowest being HVEM/TR2 (40 copies/ng total RNA), with the expression 
levels of LTR, TNFR1, and TNFR2 being 125-, 215-, and 45-fold higher than that of HVEM/TR2, 
respectively (data not shown). Rooney et al. suggested that LTR is necessary and sufficient for 
LIGHT-mediated apoptosis in a human adenocarcinoma cell line HT29 (Rooney et al., 2000). 
However, Zhai et al. reported that both LTR and HVEM/TR2 are involved cooperatively in the 
LIGHT-mediated killing of tumor cells, including HT29 cells (Zhai et al., 1998). Furthermore, it 
has been reported that only the activation of LTR by cross-linking with an anti- LTR mAb could 
induce growth arrest and chemokine production in A375 melanoma cells (Degli-Esposti et al., 
1997), although I did not observe these effects in the cells by LIGHT or LT12. This discrepancy 
might reflect different ligand sensitivity for the cell line I used. Since I did not determine whether 
the function of HVEM/TR2 is sufficient for ligand-mediated signal activation on RD cells, the 
possibility of the phenotype conversion through the HVEM/TR2 needs to be studied in more detail.  
RMS is the most frequent soft tissue malignancy in pediatric patients. It is known that several 
distinct histological subtypes of RMS have been described: alveolar, embryonal, botryoid, and 
undifferentiated (Pappo et al., 1995, Parham, 1994). Although I examined additional RMS cell lines, 
Hs729, A673, and A-204, to confirm whether LIGHT can also induce differentiation in these cell 
lines, I did not observe any effects in them (data not shown). Therefore, there might be certain RMS 
cell types which have the sensitivity to LIGHT. Several studies using RD cells have been attempted 
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to regress the phenotype by evaluating agents that alter cellular growth as well as differentiation 
both in in vitro and in vivo. Pyrimidine analogues such as GR-891 (Marchal et al., 1999) and Ara-C 
(Crouch et al., 1993) are reported to induce growth inhibition and to stimulate the differentiation 
processes and terminal myogenic differentiation of RD cells correlating with several differentiation 
markers. 
The present study may be the first to report morphological changes in RD cells induced by 
the proteinaceous reagents LIGHT and LT12. It is hoped that further investigation of these 
ligands and their potential role could lead to a novel and useful therapeutic approach for RMS. 
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Figures 
 
Figure 3. Growth inhibitory activity of LIGHT on RD cells. (A) RD cells were treated with 
varying concentrations of LIGHT (◆), TNF (■), LT (▲), LT12 (●), and LT plus LT1 
2 (×) for 4 days, and OD 450 nm/690 nm was measured by a plate reader to determine the amount 
of BrdU incorporation. (B) RD cells (105 cells/well) were cultured for 6 days with 50 ng/ml of each 
ligand, and the viable cells in each well were counted after staining with trypan blue. (C) RD cells 
cultured with or without 50 ng/ml LIGHT for 3 days were stained with propidium iodide for 30 min 
at room temperature, and after establishing fractionated mononuclear cell populations, the DNA 
content of the cells was determined by flow cytometry. FI, fluorescence intensity. 
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Figure 4. Morphology of each of the samples of ligand-treated RD cells. Each phase-contrast 
image represents control RD cells (A), RD cells treated with 50 ng/ml LIGHT (B), LT12 (C), 
LT (D), LT plus LT12 (E), or 100 mg/ml TPA (F) for 5 days. All images were acquired 
at the same magnification using a × 10 objective lens.  
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Figure 5. Chemokine production of RD cells by LIGHT. RD cells were cultured with the 
indicated concentrations of each ligand for 2 and 3 days. IL-8 and RANTES were measured by each 
specific ELISA kit.  
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Figure 6. NF-B transcriptional activity of LIGHT on RD cells. RD cells transfected with 0.5 
mg of pNF-B-SEAP vector (Clontech) were cultured with 50 ng/ml LIGHT (■), LT12 (●), 
TNF (×), LT (-), LT plus LT12 (▲), or the control (◆) for the indicated times. After the 
treatment, the SEAP activity in culture media was determined using a Great EscAPe 
chemiluminescence detection kit.  
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Figure 7. Expression of muscle-specific genes in RD cells by LIGHT. After the RD cells were 
cultured with 50 ng/ml of each ligand or 100 mg/ml of TPA for 6 days, RT-PCR was performed on 
each sample of cells using primers specific for SM -actin, Id-1, myogenin, -actin, and rRNA. The 
PCR products were resolved on 1% agarose gel containing ethidium bromide to stain the DNA.
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Figure 8. Expression of skeletal muscle-specific myosin heavy chain proteins in TPA- and 
LIGHT-treated RD cells. (A) RD cells plated onto coverslips were cultured with or without 50 
ng/ml of each ligand or 100 mg/ml of TPA for 6 days. After being fixed, each treated sample of 
cells was stained with an anti-skeletal muscle-specific myosin heavy chain mAb MY-32. All images 
were acquired at the same magnification using a × 10 objective lens. (B) For Western blot 
analysis, each ligand-treated sample of cells was cultured for 6 days and lysed, and for each a 50 mg 
protein extract was used for Western blot analysis with MY-32 mAb.  
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Part II 
Selective Androgen Receptor Modulator Activity of a Steroidal Antiandrogen TSAA-291 
and its Cofactor Recruitment Profile  
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Abstract 
 
SARM specifically binds to the AR and exert agonistic or antagonistic effects on target 
organs. In this study, I investigated the SARM activity of TSAA-291, previously known as a 
steroidal antiandrogen, in mice because TSAA-291 was found to possess partial AR agonist activity 
in reporter assays. In addition, to clarify the mechanism underlying its tissue selectivity, I 
performed comprehensive cofactor recruitment analysis of AR using TSAA-291 and DHT, an 
endogenous androgen. The AR agonistic activity of TSAA-291 was more obvious in reporter assays 
using skeletal muscle cells than in those using prostate cells. In castrated mice, TSAA-291 
increased the weight of the levator ani muscle without increasing the weight of the prostate and 
seminal vesicle. Comprehensive cofactor recruitment analysis via M2H methods using 293T cells 
revealed that among a total of 112 cofactors, 12 cofactors including the PIAS1 were differently 
recruited to androgen receptor in the presence of TSAA-291 and DHT. Further M2H analysis using 
primary cells confirmed that TSAA-291 recruited PIAS1 to AR more potently in skeletal muscle 
cells than in prostate cells. Prostate displayed higher PIAS1 expression than skeletal muscle. Forced 
expression of the PIAS1 augmented the transcriptional activity of the AR, and silencing of PIAS1 by 
siRNAs suppressed the secretion of PSA, an androgen responsive marker. My results demonstrate 
that TSAA-291 has SARM activity and suggest that TSAA-291 may induce different 
conformational changes of the AR and recruitment profiles of cofactors such as PIAS1 compared 
with DHT to exert tissue-specific activity. 
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Introduction 
 
Androgens, such as Ts and DHT, have diverse physiological actions in men such as the 
maintenance of muscle mass/strength, sperm production, fat distribution, and sex drive (Mooradian 
et al., 1987). Various symptoms such as loss of libido, decreases in muscle mass/strength, and mood 
disorder in aging men with low blood Ts levels are improved by Ts treatment; however, Ts and 
DHT are associated with various undesirable side effects (Gooren, 2003). To overcome the 
limitations of Ts treatment, several strategies have been investigated. One major approach has been 
the development of SARM. SARM is defined as compounds that specifically bind to the AR and 
exert agonistic/antagonistic effects in a tissue-specific manner (Negro-Vilar, 1999). SARM 
displaying tissue-selective anabolic effects in muscle and the bone without exerting adverse effects 
on prostate or latent prostate cancer would be a useful therapeutic option for sarcopenia, 
osteoporosis, muscle wasting associated with cancer cachexia, and aging-associated functional 
limitations (Allan et al., 2007; Miner et al., 2007).  
While the molecular mechanism underlying the tissue selectivity of SARM activity is unclear, 
SARM activity may be understood in the context of the well-established concept of selective 
estrogen receptor modulator (SERM) activity. Shang and Brown (2002) reported that cell type- and 
promoter-specific differences in steroid receptor coactivator-1 recruitment play a critical role in 
determining SERM function in the breast and uterus and offered a paradigm for understanding the 
action of SERM in other important targets. The transcriptional activity of AR is modulated via its 
interactions with cofactors, including coactivators that enhance AR activity and corepressors that 
inhibit AR activity (Brady et al., 1999; Dotzlaw et al., 2002; Fu et al., 2000; Yang et al., 2002). 
However, to the best of my knowledge, no comprehensive cofactor recruitment analysis of AR has 
been performed with a M2H system using endogenous ligands and SARM.  
TSAA-291 is a steroidal antiandrogen previously used for BPH in Japan. In the present study, 
I investigated the SARM activity of TSAA-291 in mice because TSAA-291 was found to possess 
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partial AR agonist activity in reporter assays. In addition, to clarify the mechanism underlying its 
tissue selectivity, I performed comprehensive cofactor recruitment analysis of AR using TSAA-291 
and DHT.  
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Material and Methods 
 
Reagents 
TSAA-291 (16β-ethyl-17-hydroxyestr-4-en-3-one) and TSAA-272 
(17-hydroxy-16-isopropyl-estr-4-en-3-one) were previously synthesized in my laboratory (Goto 
et al., 1978).  
 
Animals 
Male Crj:ICR mice (5 weeks old) were purchased from Charles River Laboratories, Japan 
(Yokohama, Japan). The animals were housed in a temperature-controlled room (23°C ± 2°C) with 
a 12-h/12-h light/dark cycle and given ad libitum access to food (CE-2; CLEA Japan, Inc. Tokyo, 
Japan) and water. All procedures were performed according to protocols approved by the 
Institutional Animal Care and Use Committee of Pharmaceutical Research Division, Takeda 
Pharmaceutical Company Limited. 
 
In vivo pharmacokinetic study 
Male Crj:ICR mice were randomly assigned to treatment groups and subsequently treated 
with TSAA-291. Plasma was collected via heart puncture under anesthesia at the indicated time 
points (each time point, n = 3), and the concentration of TSAA-291 was determined by 
high-performance liquid chromatography.  
 
In vivo effects of Selective Androgen Receptor Modulator compounds on androgen-dependent 
organ weight  
Male Crj:ICR mice were castrated at the beginning of the study. A group of sham-operated 
male mice was also included as an intact control. The castrated animals were allocated into groups 
of five animals according to body weight and subsequently treated with TSAA-291, TSAA-272, or 
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vehicle for the indicated period as described in Figure 2 legends. In addition, the intact animals 
were treated with vehicle during the treatment period. The drugs were dissolved in 20% benzyl 
benzoate:corn oil (20:80, vol/vol) and administered via daily subcutaneous injections. On the day 
after the final treatment, the animals were weighed; the blood was then collected from the 
abdominal aorta under anesthesia and the mice were euthanized by decapitation. The levator ani 
muscle, prostate, and seminal vesicle were subsequently excised and weighed. 
 
The effect of TSAA-291 on the sexual behavior in castrated mice 
The effect of continuous treatment with TSAA-291 on the induction of sexual behavior in 
castrated male mice. The castrated male mice were treated with TSAA-291 (3, 10, or 30 mg/kg, 
subcutaneous) or vehicle for 11-14 days and were mated for 2 consecutive days with female mice in 
the proestruos stage on a one-on-one basis (n = 5). The induction rates of pseudopregnancy (black 
bar) and menstrual disorder (white bar) were confirmed by the observation of vaginal smears every 
morning.ΨP < 0.05 versus vehicle by Fisher’s exact test. 
 
Cell culture 
Human embryonic kidney cells (293T), human breast tumor cells (BT-474), monkey kidney 
fibroblasts (COS-7), and human prostate normal peripheral zone cells (RWPE-1) were purchased 
from the American Type Culture Collection (ATCC, Manassas, VA, USA). PrECs and SkMCs 
were purchased from Lonza Japan (Tokyo, Japan). 293T and COS-7 cells were maintained in 
DMEM (Life Technologies, Inc., Carlsbad, CA, USA), containing 10% FBS (Lot. C10031, Life 
Technologies, Inc.). BT-474 cells were maintained in RPMI1640 (Life Technologies, Inc.) 
containing HEPES and 10%FBS. RWPE-1 cells were maintained in keratinocyte serum-free 
medium containing EGF and BPE (Life Technologies, Inc.). PrECs and SkMCs were cultured in 
special media, PrEGM™ BulletKit (Lonza) and SkGM™ BulletKit (Lonza), respectively, 
according to the product description of the cells. All cell lines were maintained at 37°C in a 5%CO2 
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atmosphere. For androgen response experiments in M2H and reporter assays, to exclude the 
influence of the steroids contained in the medium, 293T, COS-7, and BT-474 cells were cultured in 
phenol red-free medium supplemented with charcoal dextran-stripped FBS (DCC-FBS) (Life 
Technologies, Inc.) before use in the assay. PrECs and SkMCs were cultured in a medium without 
BPE and EGF for 2 days to exclude the influence of the steroids contained in BPE before use in the 
assay. 
 
AR binding assays 
Radiolabeled mibolerone (3 nM) and test compounds were added to a solution containing the 
wild-type AR, and the mixture was incubated at 4C for 3 h. The bound and free forms of 
mibolerone were separated by the dextran/charcoal method. The radioactivity of bound mibolerone 
was measured, and the inhibitory rate of the test compound was calculated. The Ki value was 
calculated as follows: Ki = IC50/[1 + (Ligand)/Kd]; (Ligand) = 3 × 10−9 M, Kd = 1.82 × 10−9 M. 
 
Reporter assays 
COS-7 cells 
COS-7 cells were transfected with 2.5 μg of the FL hAR -pcDNA3.1 (hAR-pcDNA3.1) and 
2.5 μg of pGL4.12/Mouse Mammary Tumor Virus (MMTV)-LTR (pGL4.12/MMTV-LTR) using 
Lipofectamine™ 2000 (Life Technologies, Inc.), according to the manufacturer's instructions. Four 
hours after transfection, the cells were plated in each well of a 96-well plate at a density of 1 × 104 
cells/well, followed by treatment with DHT or the test compound for 4 h. The luciferase activity in 
the cells was measured using a Bright-Glo Luciferase assay kit (Promega, Madison, WI, USA) and 
a Wallac 1420 ARVO MX multi-label counter (Perkin Elmer, Waltham, MA, USA). 
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PrECs and SkMCs (primary cells) 
PrECs and SkMCs were transfected with 1.25 μg of human AR-pcDNA3.1 (hAR-pcDNA3.1) 
and 1.25 μg of human PSA2-Luc-pGL3 (hPSA2-Luc-GL3) using Lipofectamine™ LTX (Life 
Technologies, Inc.) and PLUS reagent (Life Technologies, Inc.) according to the manufacturer’s 
instructions. Six hours after transfection, the cells were seeded on 96-well poly-L-lysine–coated 
white plates at a density of 2.0 × 104 cells/well. After overnight culture, DHT or TSAA-291 was 
added and cultured for an additional 24 h. Luciferase activity was measured as described above. 
 
The effect of PIAS1 on AR transactivation 
In the reporter assays studying the effect of PIAS1 on AR transactivation, 293T cells were 
prepared as previously described. 293T cells were transfected with 1 g of hAR-pcDNA3.1 and 1 
g of 6kPSA-pGL3 together with the human PIAS1-pcDNA3.1 plasmid at the indicated 
concentration using LipofectamineTM2000. The total plasmid amount was set as 3.6 g. Four hours 
after transfection, the cells were plated in each well of a 96-well plate at a density of 1 × 104 cells / 
well and cultured for 4 h. The cells were treated with 100 nM DHT or 100 nM TSAA-291 and 
further cultured for 24 h. Luciferase activity was measured as previously described. 
 
Mammalian Two-Hybrid assays  
AR-cofactor interactions were evaluated by the Checkmate™ Mammalian Two-Hybrid 
System (Promega) in 293T cells. The Gal4-DNA binding domain was fused with FL human AR 
(hAR-pBIND vector), and the VP16 activation domain was fused to each of the cofactor genes 
(cofactor-pACT vectors). The luciferase reporter plasmid with five copies of the GAL4 binding site 
(pG5luc vector) was purchased from Promega. 293T cells were seeded in phenol red-free 
DMEM-5% DCC-FBS medium on 6-well poly-L-lysine-coated plates at a density of 8.6 × 105 
cells/well for 24 h before transfection. 293T cells were transfected with 1666 ng of hAR-pBIND, 
1666 ng of cofactor-pACT, and 1666 ng of pG5luc vector using Lipofectamine™ 2000. Six hours 
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after transfection, the cells were harvested, suspended in DMEM-5% DCC-FBS medium, and 
seeded on 96-well poly-L-lysine-coated white plates. After a 24-h culture, Ts, DHT, or the test 
compound was added to each well. After an additional 24 h of culture, luciferase activity was 
measured as described above.  
For the M2H assays with RWPE-1 cells and SkMCs, were suspended in steroid-reduced 
medium and seeded on 10-cm dishes at a density of 80% confluency for 2 days before transfection. 
RWPE-1 cells and SkMCs were transfected with 5000 ng of hAR-pBIND, 5000 ng of 
cofactor-pACT, and 5000 ng of pG5luc vectors by the same method. Six hours after transfection, 
RWPE-1 cells and SkMCs were harvested, and the cell suspensions of RWPE-1 cells or SkMCs 
were seeded on 96-well poly-L-lysine-coated white plates at a density of 5 × 104 or 2 × 104 
cells/well, respectively. After a 24-h culture, Ts, DHT, or the test compound was added to each well 
at 10 pM to 3 M. After an additional 24-h culture, luciferase activity was measured as described 
above. 
 
BT-474 PSA assays 
Silencing using 15 nM siRNA was performed using LipofectamineTM RNAiMAX (Life 
Technologies, Inc.) via the reverse transfection method according to the manufacturer’s protocol. 
The following three types of PIAS1 siRNAs were used:  
5′-CCUUACGACUUACAAGGAUUAGAUU-3′(siRNA#1),  
5′-UAUUCACUUUCACACAAAGAUUGGG-3′(siRNA#2),  
5′-GGUCCAGUUAAGUUUGU-3′(siRNA#3) (Life Technologies, Inc). The Silencer® Select 
Negative Control No. 2 siRNA is used as a non-targeting negative control (Life Technologies, Inc). 
Twenty-four hours after siRNA transfection, DHT (0.1, 1, 10, or 100 nM) was added. The amount 
of PSA in the conditioned medium was determined using an ELISA kit (Dainippon Pharmaceutical, 
Osaka Lapan). 
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Quantitative real-time PCR 
The gene expression levels of cofactors were quantified by quantitative real-time PCR. Total 
RNA of human normal prostate (lot No. 7060206) and skeletal muscle tissue (lot No. 8062503A) 
was purchased from Clontech Laboratories (Mountain View, CA, USA). Each cDNA for these total 
RNAs was synthesized in vitro using the SuperScript First-Strand Synthesis System (Life 
Technologies, Inc). Quantification of cDNA (100 ng total RNA/µl) was performed using the 
TaqMan® Low Density Array containing the ready-made primers and probes optimized for TaqMan 
PCR (Life Technologies, Inc) with the ABI Prism 7900HT Fast Real-Time PCR System (Life 
Technologies, Inc). The gene expression levels of PIAS1 in primary cells were quantified by 
quantitative real-time PCR using the ready-made primers and probes optimized for PIAS1 (Life 
Technologies, Inc). The total RNA of primary cells (PrECs, RWPE-1 cells, and SkMCs) was 
isolated using an RNeasy Mini Kit (QIAGEN Japan, Tokyo, Japan). In this study, 18S rRNA was 
used as the internal standard to normalize the amount of mRNA used for PCR. Data were analyzed 
by the qualitative standard method using RQ Manager 1.2 software (Life Technologies, Inc). 
 
Statistical analysis 
Data are presented as the mean ± S.E.M.. Comparisons between two groups were performed 
using Student’s t-test. Comparisons between multiple groups were performed using Dunnett’s t-test. 
A P-value < 0.05 (two-tailed) was considered statistically significant.  
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Results 
 
In vitro properties 
TSAA-291 and TSAA-272, another steroidal compound with a similar SARM profile as 
TSAA-291, had similar binding affinities for androgen receptor, with Ki values of approximately 
1.4 and 1.2 nM, respectively, whereas the Ki value of DHT was 0.28 nM (Table 1).  
In the reporter assays using COS-7 cells, TSAA-291, and TSAA-272 exhibited antagonist 
activity in the presence of 100 nM DHT (Figure 9A), whereas TSAA-291 and TSAA-272 partially 
stimulated the reporter, in the absence of DHT, by approximately 50% at maximum relative to the 
maximal stimulation induced by 1 μM DHT (Figure 9A). 
In the reporter assay in PrECs and SkMCs, which are derived from the prostate and muscle, 
respectively, TSAA-291 induced maximum AR activation that was more similar to that of DHT in 
SkMCs than in PrECs (Figure 9B). According to the clinical data of TSAA-291, the plasma level of 
TSAA-291 after weekly intramuscular administration at 400 mg/kg for 12 weeks is approximately 
100 nM (Drug Information). The agonist activity of TSAA-291 at 100 nM was 47.5% of that of 
DHT at the same concentration in PrECs (Figure 9B), whereas the agonist activity of TSAA-291 
was 87.6% of that of DHT in SkMCs (Figure 9B).  
Based on these data, I reasoned that TSAA-291 may have SARM profile in vivo and studied 
the SARM activity in mice.  
 
Tissue specific effect of TSAA-291 in castrated mice 
First, I monitored the plasma level of TSAA-291 after a single administration. Plasma 
TSAA-291 levels were dose-dependently elevated with a subcutaneous dosing at 10 and 30 mg/kg 
(Figure 10A). TSAA-291 treatment at 30 mg/kg was sufficient to maintain a plasma concentration 
of 100 nM for approximately 15 h (Figure 10A). Daily subcutaneous administration of 10 and 30 
mg/kg TSAA-291 markedly increased the weight of the levator ani muscle in a dose-dependent 
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manner in castrated mice (Figure 10B), and TSAA-291 at 30 mg/kg increased the levator ani 
muscle weight to 78% of that in the intact animals (P < 0.001, Figure 10B). In contrast, no marked 
weight increase in the prostate was observed after the treatment of castrated mice with TSAA-291 
at doses of up to 30 mg/kg (Figure 10B). Similar results were obtained after the treatment of 
castrated mice with TSAA-272 at a dose of 30 mg/kg (Figure 10C). Treatment with TSAA-291 at 
doses of 3 to 30 mg/kg also showed tendency to induce libido and sexual behavior in castrated male 
mice (Figure 11). These results indicate that TSAA-291 has tissue-specific effects and functions as 
SARM. 
 
Comprehensive cofactor recruitment analysis  
The molecular mechanism of the tissue selectivity of SARM has not been completely 
clarified. I hypothesized that the selectivity is the result of the different patterns of cofactor 
recruitment to AR induced by ligands. I constructed a comprehensive M2H system with FL human 
AR and a total of 112 cofactors in 293T cells (Figure 12A, Table 2) and assessed the effects of 
TSAA-291, TSAA-272, Ts, and DHT on the cofactor recruitment to AR. These cofactors were 
selected from the cofactors in literature information, not only related with androgen receptor but 
also related with other nuclear receptors such as estrogen receptor, progesterone receptor, and 
peroxisome proliferator-activated receptor. Fifty-seven cofactors did not bind to AR (no binding 
type; Table 2, Figure 12B). Among the 55 cofactors that bound to AR, 43 cofactors exhibited no 
difference of recruitment to AR in the presence of TSAA-291 and DHT (ligand-independent type; 
Table 2, Figures 12C and 13). Typical examples of the cofactor recruitment with the no binding 
type and ligand-independent type are shown in Figure 12B, C, respectively. The other 12 cofactors 
(PIAS1, PIAS4, PIAS3, FLNA, FHL2, TAF1, NCOA1, PNRC, DAXX, SENP1, PAK6, and 
COX5B) were recruited to AR by TSAA-291 and TSAA-272 in a different manner than that 
observed for Ts and DHT (ligand-dependent type: Table 2, Figure 14). These results suggest that 
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AR may undergo a different conformational change when bound by SARM compared with 
endogenous androgens. 
 
PIAS1 is recruited to AR differentially by TSAA-291 and endogenous androgens 
Among the 12 ligand-dependent cofactors, the recruitment of PIAS1 to AR exhibited 
strikingly different patterns in the presence of SARM and endogenous androgens (Figure 14). The 
dose-response curve of the recruitment of PIAS1 to AR after treatment with TSAA-291 and 
TSAA-272 was right-shifted compared with that with endogenous androgens (Figure 14). The 
levels of PIAS1 recruitment induced by TSAA-291 and TSAA-272 at 100 nM were 56 and 58%, 
respectively, relative to that induced by DHT at 100 nM (Figure 14). I also examined the 
recruitment of PIAS1 to AR in RWPE-1 cells and SkMCs, which are derived from the prostate and 
skeletal muscle, respectively, and are supposed to possess the intracellular environments of the 
respective target organs. TSAA-291 and TSAA-272 recruited PIAS1 to AR at lower concentrations 
and to a larger extent in SkMCs than in RWPE-1 cells (Figure 15). PIAS1 recruitment to AR by 
TSAA-291 and TSAA-272 at 100 nM represented 13.9 and 18.8%, respectively, of that induced by 
DHT at 100 nM in RWPE-1 cells (Figure 15). On the contrary, in SkMCs, PIAS1 recruitment to 
AR by TSAA-291 and TSAA-272 at 100 nM represented 102.2 and 92.4%, respectively, of that 
induced by DHT at 100 nM (Figure 15). Other ligand-dependent type of cofactors such as PIAS3, 
PIAS4, and SENP1 also exhibited different AR recruitment pattern by TSAA-291 in SkMCs and 
RWPE-1 cells (Figure 15), although only PIAS1 was the cofactor that was most strikingly recruited 
to AR by TSAA-291 at 100 nM in SkMCs (Figure 15). These results suggest that AR may undergo 
a different conformational change when bound by SARM versus endogenous androgens and that 
the different recruitment of cofactors such as PIAS1 to AR by SARM, and endogenous androgens 
as well as its different cofactor recruitment to AR between target tissues may be responsible for the 
tissue selectivity of SARM.  
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PIAS1 acts as a coactivator of AR 
I confirmed the expression of PIAS1 in RWPE-1 prostate cells and SkMCs. Prostate cells 
displayed higher PIAS1 expression than skeletal muscle cells (Figure 16A). In addition, I confirmed 
the gene expression of several cofactors in prostate and skeletal muscle tissue. The expression level 
of PIAS1 in prostate tissue was higher than that in skeletal muscle (Figure 16B), and the expression 
level of COX5B in skeletal muscle was higher than that in prostate tissue (Figure 16B). Finally, I 
investigated whether PIAS1 is a coactivator or corepressor of the AR in my reporter assay using 
293T cells. Cotransfection of increasing amounts of the PIAS1 vector augmented the transcriptional 
activity of the AR in the presence of DHT (Figure 17A). I also confirmed that the transfection of 
PIAS1 enhanced the transcriptional activity of the AR in the presence of TSAA-291 (Figure 17A), 
although the extent of the increase induced by TSAA-291 was lower than that induced by DHT 
(Figure 17A). In addition, silencing of PIAS1 by siRNAs suppressed DHT-induced PSA secretion 
in BT-474 cells (Figure 17B). The knockdown efficiency of PIAS1 mRNA levels by each PIAS1 
siRNA was confirmed (Figure 17C). PIAS1 siRNA also inhibited the mRNA expression of PSA 
(data not shown). These results indicate that PIAS1 acts as a coactivator of the AR. Cofactors such 
as PIAS1 might contribute to the tissue selectivity of some SARM compounds.  
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Discussions 
 
SARM is defined as tissue-selective androgen receptor ligands. Several groups recently 
discovered a structurally distinct class of orally active nonsteroidal compounds that exert weaker 
effects on the prostate while maintaining anabolic effects in muscle and the bone (Allan et al., 2007; 
Miner et al., 2007; Vajda et al., 2009). In the present study, I first observed that TSAA-291, a 
steroidal antiandrogen previously used to treat BPH in Japan, displayed partial agonist activity in 
reporter assays using COS-7 cells (Figure 9A). In addition, I found that the maximum AR agonist 
activity of TSAA-291 was almost comparable to that of DHT in the reporter assays using skeletal 
muscle cells, whereas in prostate cells, the agonist activity of TSAA-291 was approximately half of 
that of DHT (Figure 9B). Based on these findings, I reasoned the different in vitro activities in the 
prostate and muscle cells may reflect the in vivo profile of TSAA-291. As expected, I observed that 
the administration of TSAA-291 at 10 and 30 mg/kg markedly increased the weight of the levator 
ani muscle without increasing that of the prostate and seminal vesicle in castrated mice, 
demonstrating that TSAA-291 has SARM properties in mice (Figure 10B, C). In addition, I also 
observed that the treatment of castrated male mice with TSAA-291 at 3-30 mg/kg exhibited 
tendency to induce sexual behavior (Figure 11). The effective concentrations of TSAA-291 in 
clinical situations, mouse models, and cell models are consistent. The plasma level of TSAA-291 
after weekly intramuscular administration at 400 mg/kg for 12 weeks in patients is approximately 
100 nM (Drug Information), while TSAA-291 administration at 30 mg/kg was sufficient to 
maintain the plasma concentrations of 100 nM for approximately 15 h in mice (Figure 10A). A 
cellular response in reporter and M2H assays was also observed for 100 nM TSAA-291(Figures 9B, 
14, and 15). 
The SARM activity of TSAA-291 may not be due to differences in tissue distribution because 
it is reported that the 3H-TSAA-291 levels in the levator ani muscle and ventral prostate after the 
treatment of rats with 3H-TSAA-291 were approximately identical (Sudo et al., 1981).  
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The molecular mechanisms underlying the tissue-specific activity of SARM are unclear. I 
hypothesized that the tissue selectivity results from different AR conformational changes induced 
by SARM and full agonists and that the different AR conformation could be revealed by differences 
in cofactor recruitment profiles. To test these hypotheses, I performed comprehensive M2H cofactor 
recruitment analysis. The results illustrated that the recruitment pattern of 12 cofactors to AR was 
different between SARM and endogenous androgens (Figure 14). These data suggest that SARM 
and endogenous androgens may induce different conformational changes of the AR, and the altered 
AR conformation induced by the different ligands might facilitate the recognition of different DNA 
motifs, leading to differences in gene transcription levels. Considering the lower affinity of 
TSAA-291/272 than DHT/Ts for the AR, the other ligand-independent type cofactors such as 
growth arrest and DNA damage-inducible gamma (GADD45G), growth arrest and DNA 
damage-inducible alpha (GADD45A), nuclear transcription factor Y gamma (NFYC), peroxisome 
proliferative activated receptor gamma coactivator 1 beta (PPARGC1B), spen family transcriptional 
repressor (SPEN), and nuclear receptor subfamily 0 group B member 2 (NR0B2), which display 
overlapped dose-response curves in M2H assays (Figure 12C and Table 2), might also contribute to 
the differences in conformation of the AR. 
The 12 cofactors displaying different recruitment profiles between endogenous androgens and 
TSAA-291 in the present study were categorized as follows: PIAS family, post-translational 
modifications-related molecules, cell cycle regulating protein, cell cytoskeleton-related protein, and 
others. PIAS family genes reportedly interact with the DNA-binding domain of androgen receptor 
(Moilanen et al., 1999) and regulate the receptor’s transcriptional activity (Gross et al., 2001). 
Among them, recruitment profiles of PIAS1 to AR between endogenous androgens and 
TSAA-291were significantly different in both M2H assay system using 293T cells and primary 
cells (Figures 14 and 15), however, the effects of PIAS family proteins on AR-dependent 
transcriptional activity are controversial. It has been reported that PIAS1 functions as an AR 
coactivator in prostate cancer cells (Gross et al., 2001), whereas PIAS1 acts as a SUMO-E3 ligase 
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for AR and represses AR-dependent transactivation via sumoylation in U2OS human osteosarcoma 
cells (Nishida and Yasuda, 2002). I confirmed that PIAS1 functioned as a coactivator of AR (Figure 
17A, B). The more potent AR transactivation induced by TSAA-291 in the reporter assay using 
skeletal muscle cells than observed using prostate cells may be because of greater PIAS1 
recruitment to AR in response to TSAA-291 in skeletal muscle cells. The interaction between the 
AR and PIAS1 as assessed using co-IP assays has recently been reported (Toropainen et al., 2015). 
The interaction between the AR and PIAS1 in the presence of TSAA-291 and DHT as well as the 
type of intracellular environment factors responsible for the different sensitivity in prostate and 
skeletal muscle cells remains to be elucidated.  
The differential expression levels of AR cofactor genes might also be responsible for a 
potential mechanism of tissue specificity. Prostate cells exhibited higher PIAS1 expression than 
skeletal muscle cells. The higher expression of PIAS1 and greater recruitment of PIAS1 to the AR 
induced by DHT in prostate cells might explain the prostate-oriented activity of DHT. On the 
contrary, the expression level of COX5B in skeletal muscle was higher than that in prostate tissue 
(Figure 16B). The recruitment of COX5B to the AR in muscle cells but not prostate cells is not 
different in the presence of TSAA-291 and DHT at 100 nM (Figure 14). Cofactors such as COX5B 
might account for the agonist activity of the AR in skeletal muscle. 
PIAS1 has the characteristics of a scaffold/matrix attachment region-binding protein (Bode et 
al., 2000; Kipp et al., 2000). As scaffold attachment factors, PIAS family proteins may control the 
modulatory functions of many proteins and mediate interaction between different signaling 
pathways. I speculate that, at least in the case of TSAA-291, greater AR activation via higher 
recruitment of PIAS1 and other cofactors to AR in skeletal muscle cells than in prostate cells may 
lead to high anabolic/androgenic ratio profile in vivo. Further investigation on the functional role of 
PIAS1 or PIAS family proteins in the tissue selectivity of SARM is required. In addition, proteomic 
analysis of AR-bound coregulators in different cell lines could provide more insight into the 
tissue-specific effects of SARM. 
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Another possible mechanism for the tissue selectivity of TSAA-291 is steroidal metabolism 
in tissues. The activity of 5-reductase is essential for DHT production from Ts. 5-reductase is 
present in the prostate but not in muscle (Yamana and Labrie, 2010). The localization of this 
enzyme may be involved in the SARM profile of TSAA-291. A substantial portion of TSAA-291 
may be converted to 5-DHTSAA-291, a reduced form of TSAA-291, by 5-reductase in the 
prostate (Sudo et al., 1981), whereas TSAA-291 itself may be the dominant form in muscle. I 
obtained data illustrating that 5-DHTSAA-291 possesses high AR binding affinity compared with 
TSAA-291, markedly lower AR agonistic activity than TSAA-291 in reporter assays, and no effect 
on the weight of the prostate and levator ani muscle in castrated mice (data not shown). 
It was reported that the coactivator GR-interacting protein 1 (GRIP-1) does not completely 
enhance SARM-mediated transcriptional activity but completely enhances full agonist-mediated 
transcription (Miner et al., 2007). I also evaluated the recruitment of GRIP-1 by TSAA-291 and 
endogenous androgens using my constructed M2H system. However, a clear difference between 
each ligand was not observed. The reason for this is currently unclear; however, the discrepancy 
may be explained by the different cell lines used for the M2H assay. 
Reducing sex hormone levels by treatment with LHRH analogs is currently used in men to 
treat hormone-responsive prostate cancer and in women to treat uterine fibroids, endometriosis, and 
hormone receptor-positive premenopausal breast cancer. These treatments cause side effects such as 
accelerated bone loss with an increased risk of skeletal fractures, loss of libido, sexual behavior, 
depression, heart attacks, cardiovascular disease, or hot flashes (Harle et al., 2006; Higano, 2003; 
Sharma and Muggia, 2013; Smith et al., 2001). My data suggest that TSAA-291 has anabolic 
effects on skeletal muscle and induce sexual interest with limited harmful androgenic effects. 
Combination treatment with TSAA-291 and LHRH analogs may represent a useful therapeutic 
option for sex hormone-dependent diseases. 
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In conclusion, I found that TSAA-291, a steroidal antiandrogen previously used for BPH 
patients in Japan, has SARM activity, and my comprehensive cofactor recruitment analysis suggests 
that TSAA-291 may induce different conformational change of AR compared with DHT.  
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Tables 
 
Table 1. Chemical structure and binding affinity to the AR. Radiolabeled mibolerone (3 nM) 
and test compounds (TSAA-291, TSAA-272, and DHT) were added to a solution containing the 
wild-type AR and incubated at 4C for 3 h. Bound and free forms of mibolerone were separated by 
the dextran/charcoal method. The radioactivity of bound mibolerone was measured, and the 
inhibitory rate of the test compound was calculated. 
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Table 1 
 
  
TSAA-291 TSAA-272 DHT
Structure
Ki
（nM） 1.4 1.3 0.28
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Table 2. Cofactor list and recruitment to AR. The cofactors used for the M2H analysis and their 
recruitment to AR are summarized. “No binding to AR” indicates that the cofactor did not bind to 
AR. “Ligand independent” indicates that the cofactor was recruited to AR in a ligand-independent 
manner. “Ligand dependent” indicates that the cofactor was recruited to AR in a ligand-dependent 
manner.  
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Table 2  
No binding to AR
Gene ID
amino-terminal enhancer of split AES
COP9 signalosome subunit 2 COPS2
amyloid beta precursor protein (cytoplasmic tail) binding protein 2 APPBP2
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 APPL1
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 APPL2
RAN, member RAS oncogene family RAN
nuclear receptor binding SET domain protein 1 NSD1
SWI/SNF related,matrix associated, actin dependent regulator of chromatin, subfamily d,member 3 SMARDC3
bromodomain containing 8 BRD8
calreticulin CALR
RNA binding motif protein 39 RBM39
cyclin D1 CCND1
anti-silencing function 1A histone chaperone ASF1A
C-terminal-binding protein CTBP
nuclear receptor coactivator 7 NCOA7
EF-hand calcium binding domain 6 EFCAB6
growth arrest and DNA-damage-inducible, beta GADD45B 
gelsolin GSN
PSMC3 interacting protein PSMC3IP
histone deacetylase 1 HDAC1
histone deacetylase 3 HDAC3
high mobility group AT-hook 1 HMGA1
DDB1 and CUL4 associated factor 6 DCAF6
COP9 signalosome subunit 5 COPS5
ribosomal protein L7 RPL7
ligand dependent nuclear receptor corepressor LCOR
lipin 1 LPIN1
multiprotein bridging factor 1 MBF1
paired box 8 PAX8
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Table 2  
No binding to AR
Gene ID
mediator complex subunit 24 MED24
SNW domain containing 1 SNW1
integrin beta 3 binding protein (beta3-endonexin) ITGB3BP
PRKC, apoptosis, WT1, regulator PAWR
parkinson protein 7 PARK7
protein arginine methyltransferase 1 PRMT1
protein arginine methyltransferase 2 PRMT2
pre-mRNA processing factor 6 PRPF6
splicing factor proline/glutamine-rich SFPQ
proteasome (prosome, macropain) 26S subunit, ATPase, 3 PSMC3
protein tyrosine kinase 2 beta PTK2B
ring finger and CHY zinc finger domain containing 1, E3 ubiquitin protein ligase RCHY1
prohibitin 2 PHB2
squamous cell carcinoma antigen recognized by T cells 3 SART3
SET domain, bifurcated 1 SETDB1
nuclear receptor corepressor 2 NCOR2
speckle-type POZ protein SPOP
sex determining region Y SRY
SCAN domain containing 1 SCAD1
C1D nuclear receptor corepressor CID
supervillin SVIL
transcription factor 4 TCF4
K(lysine) acetyltransferase 5 KAT5
thyroid hormone receptor interactor 13 TRIP13
tubulin, beta class I TUBB
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta YWHAB
mediator complex subunit 17 MED17
X-ray repair complementing defective repair in Chinese hamster cells 5 XRCC5
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Table 2  
Ligand independent
Gene ID
transcriptional adaptor 3 ADA3
TATA element modulatory factor 1 ARA160
transforming growth factor beta 1 induced transcript 1) ARA55
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 ) CBP
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 CITED1
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 CITED2
catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1
mediator complex subunit 14 DRIP150
forkhead box O3 FOXO3
growth arrest and DNA-damage-inducible, alpha GADD45A
growth arrest and DNA-damage-inducible, gamma GADD45G
glutamate receptor interacting protein 1 GRIP1
LIM domain only 4 LMO4
proteasome (prosome, macropain) 26S subunit, ATPase, 4 PSMC4
K(lysine) acetyltransferase 7 KAT7
nuclear receptor corepressor 1 NCoR1
nuclear transcription factor Y, gamma NFYC
nemo-like kinase NLK
nuclear receptor subfamily 2, group F, member 2 NR2F2
K(lysine) acetyltransferase 2B CAT2B
SMAD family member 3 (SMAD3) SMAD3
peroxisome proliferative activated receptor, gamma, coactivator 1 beta PPARGC1B
protein inhibitor of activated STAT, 2 PIAS2
proline-rich nuclear receptor coactivator 1 PNRC1
receptor of activated protein kinase C 1 RACK1
nuclear receptor coactivator 6 NCOA6
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Table 2  
Ligand independent
Gene ID
nuclear receptor interacting protein 1 NRIP1
splicing factor 1 SF-1
spen family transcriptional repressor SPEN
nuclear receptor subfamily 0, group B, member 2 NR0B2
SIN3 transcription regulator family member A SIN3A
decapping mRNA 1A DCP1A
nuclear receptor coactivator 3 NCOA3
nuclear receptor subfamily 2, group C, member 2 NR2C2
mediator complex subunit 1 MED1
proteasome (prosome, macropain) 26S subunit, ATPase, 5 PSMC5
thyroid hormone receptor interactor 6 TRIP6
tumor susceptibility 101 TSG101
SAM pointed domain containing ETS transcription factor SPDEF
ubiquitin-conjugating enzyme E2I UBE2I
ubiquitin-like modifier activating enzyme 3 UBA3
ubiquitously-expressed, prefoldin-like chaperone UXT
zinc finger, MIZ-type containing 1 ZMIZ1
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Table 2  
Ligand dependent
Gene ID
Cytochrome c oxidase subunit Vb COX5B
death-domain associated protein DAXX
four and a half LIM domains 2 FHL2
filamin A, alpha FLNA
nuclear receptor coactivator 1 NCOA1
protein inhibitor of activated STAT, 1 PIAS1
protein inhibitor of activated STAT, 3 PIAS3
protein inhibitor of activated STAT, 4 PIAS4
proline-rich nuclear receptor coactivator 2 PNRC
SUMO1/sentrin specific peptidase 1 SENP1
P21 potein-activated kinase 6 PAK6
TAF1 RNA polymerase II,TATA box binding protein (TBP)-associated factor, 250kDa TAF1
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Figures 
 
Figure 9. In vitro AR transcriptional activity of SARM compounds. (A) The reporter assay 
using COS-7 cells. Agonist activity (○) and antagonist activity (●). The agonistic activities are 
shown relative to those of the 1 μM DHT treatment as 100%. The antagonistic activities by test 
compound are shown relative to those of the 0.1 μM DHT treatment as 100%. Data are shown as 
the mean ±S.E.M. (n = 3). (B) The reporter assay using human prostate epithelial and human 
skeletal muscle cells. The concentration of DHT (●) or TSAA-291 (■) was from 0.1 pM to 1 μM. 
The ordinate values are expressed as RLU, setting the value of the DMSO control as 1. Data are 
shown as the mean ± S.E.M. (n = 3). 
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Figure 9  
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Figure 10. Tissue specific effect of TSAA-291 in castrated mice. (A) Pharmacokinetic data of 
TSAA-291. Male mice were treated with 10 mg/kg (dotted line) or 30 mg/kg (solid line) of 
TSAA-291 subcutaneously for 1, 2, 4, 7, or 24 h. The plasma concentration of TSAA-291 was 
determined by HPLC. Data are shown as the mean ± S.E.M. (n = 3). (B) The effect of continuous 
treatment with TSAA-291 on the weights of androgen-responsive tissues in castrated male mice. 
The castrated male mice (n = 5) were treated with TSAA-291 (3, 10, or 30 mg/kg, subcutaneous) or 
vehicle for two weeks. In addition, the intact animals were treated with vehicle during the treatment 
period (n = 6). On the day after the final treatment, each tissue was excised and weighed. (C) The 
effect of continuous treatment with TSAA-272 on the weights of androgen-responsive tissues in 
castrated male mice. The castrated male mice (n = 5) were treated with TSAA-272 or TSAA-291 
(30 mg/kg, subcutaneous) or vehicle for seven days. In addition, the intact animals were treated 
with vehicle during the treatment period (n = 5). On the day after the final treatment, each tissue 
was excised and weighed. Data are shown as the mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 
0.001, versus vehicle by Dunnett’s t-test; ###P < 0.001 versus vehicle by Student’s t-test. 
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Figure 11. The effect of TSAA-291 on the sexual behavior in castrated mice. The effect of 
continuous treatment with TSAA-291 on the induction of sexual behavior in castrated male mice. 
The castrated male mice were treated with TSAA-291 (3, 10, or 30 mg/kg, subcutaneous) or vehicle 
for 11-14 days and were mated for 2 consecutive days with female mice in the proestruos stage on a 
one-on-one basis (n = 5). The induction rates of pseudopregnancy (black bar) and menstrual 
disorder (white bar) were confirmed by the observation of vaginal smears every morning. ΨP < 0.05 
versus vehicle by Fisher’s exact test.  
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Figure 12. Typical examples of the cofactor recruitment with the no binding type and 
ligand-independent type in M2H assays. (A) Schematic representation of M2H assays. (B) The 
binding between AR and each cofactor was measured by M2H assays. 293T cells were transfected 
with pBIND, pACT, and pG5luc vectors (vector control) or with pBIND-Id, pACT-MyoD and 
pG5luc vectors (positive control) or with hAR-pBIND, cofactor-pACT, and pG5luc vectors. (C) 
Typical examples of the cofactor recruitment with ligand-independent type (DHT, ●  and 
TSAA-291, ▲) were shown. (B, C) The ordinate values are expressed as RLU, setting the value of 
the vector control as 1. Data are shown as the mean ± S.E.M. (n = 3). 
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Figure 13. The ligand-independent cofactor analysis. 293T cells were transfected with 
hAR-pBIND, cofactor-pACT, and pG5luc vectors using LipofectamineTM2000. After treatment with 
varying concentrations of SARM compounds (TSAA-291, ▲) or endogenous androgens (DHT, ●) 
for 24 h, luciferase activity in the cells was measured. Ordinate values are expressed as RLU, 
setting the value of the DMSO control as 1. Data are shown as the mean ± S.E.M. (n = 3). 
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Figure 14. Comprehensive cofactor recruitment analysis. 293T cells were transfected with 
hAR-pBIND, cofactor-pACT, and pG5luc vectors using LipofectamineTM2000. After treatment 
with varying concentrations of SARM compounds (TSAA-291, ▲  and TSAA-272, ▼ ) or 
endogenous androgens (DHT, ● and Ts, ■) for 24 h, luciferase activity in the cells was 
measured. Ordinate values are expressed as RLU, setting the value of the DMSO control as 1. Data 
are shown as the mean ± S.E.M. (n = 3). 
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Figure 15. M2H analysis using primary cells. RWPE-1 cells and SkMCs were transfected with 
hAR-pBIND, PIAS1-pACT, and pG5luc vectors using LipofectamineTM LTX PLUS. After 
treatment with varying concentrations of SARM compounds (TSAA-291, ▲ and TSAA-272, ▼) 
or endogenous androgens (DHT, ● and Ts, ■) for 24 h, luciferase activity in the cells was 
measured. The ordinate values are expressed as RLU, setting the value of the DMSO control as 1. 
Data are shown as the mean ± S.E.M. (n = 3).   
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Figure 16. The expression levels of cofactors. (A) PIAS1 expression levels were measured in 
PrECs, RWPE-1 cells, and SkMCs by a quantitative real-time PCR method. 18S rRNA was used as 
the internal standard to normalize the amount of mRNA. Data were analyzed by the qualitative 
standard method and were shown relative to those of PrECs as 1. (B) The cofactors displaying 
different recruitment profiles between DHT and TSAA-291 expression levels were measured in 
normal prostate and skeletal muscle by a quantitative real-time PCR method. 18S rRNA was used 
as the internal standard to normalize the amount of mRNA. Data were analyzed by the qualitative 
standard method and were shown cofactor mRNA ratio against 18S rRNA 
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Figure 17. PIAS1 as a coactivator of AR. (A) The effect of PIAS1 overexpression on AR 
transcriptional activity in the presence of DHT or TSAA-291. 293T cells were transfected with 1 μg 
of hAR-pcDNA3.1 and 1 μg of 6kPSA-pGL3 together with PIAS1-pcDNA3.1 at the indicated 
concentration using LipofectamineTM 2000. Total plasmid amount was set at 3.6 μg. 293T cells 
were treated with DHT (●; 100 nM) or TSAA-291(■; 100 nM) for 24 h, and then, luciferase 
activity was measured. The ordinate values are expressed as RLU, setting the value of the each 
mock control (without PIAS1 plasmid at DHT_100nM or TSAA-291_100nM) as 1. Data are shown 
as the mean ± S.E.M. (n = 3). (B) The effect of knockdown of PIAS1 by siRNA on PSA secretion in 
BT-474 cells. Knockdown by 15 nM of siRNA (●; control siRNA , ▲; PIAS1 siRNA#1, ■; 
PIAS1 siRNA#2, ◆; PIAS1 siRNA#3) was performed using LipofectamineTM RNAiMAX by the 
reverse transfection method. Twenty-four hours after siRNA transfection, DHT (0.1, 1, 10, and 100 
nM) was added. After 6 days of culture, the amount of PSA in the conditioned medium was 
determined. (C) The knockdown efficiency was examined using the mRNA sample after 48 h of 
transfection by the quantitative real-time PCR TaqMan method. 18S rRNA was used as the internal 
standard to normalize the amount of mRNA. The ordinate values are shown relative to those of the 
control siRNA treatment as 1. Data are shown as the mean ± S.E.M. (n = 3). 
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General Discussion  
 93 
 
In this study, I focused attention on the transcriptional-mediated cell signaling which alters or 
modifies cellular functions through induction or suppression of gene expression. TNF and AR are 
representative players of it and disruption or dysfunction of pathway components including them is 
well known to cause various diseases including cancers. Huge efforts have been made to target 
these molecules and pathways for new medication, but there still remain unidentified mechanisms 
underlying them. Identification of anti-proliferative effect of LIGHT on RMS (part I) and SARM 
profile of AR ligand TSAA-291 (part II) served as initial steps toward elucidation of novel 
mechanisms related with TNF and AR signaling as discussed below. 
In part I, I firstly identified that LIGHT binds with two known receptors, HVEM/TR2 and 
LTR, and induces dramatic morphological change in a human RMS cell line, RD. The change in 
the morphology was characterized further as growth delay with elongated cytoplasm hypertrophy 
(Figures 3 and 4) and increased SM -actin expression (Figure 7). Interestingly, LT12, which is 
specifically bound to LTR showed similar results, but TNF or LTdid not (Figures 3, 4, and 7). 
Both LIGHT and LT12 stimulated the transcriptional activity of NF-B and the expression of 
NF-B-responsive proteins, such as IL-8 and RANTES. Those effects were relatively weak in 
compared with TNF or LT (Figures 5 and 6), indicating that the activated NF-B plays only a 
minor role in the morphological change and growth delay of RD cells by LIGHT or LT12 
treatment. My data showed that LIGHT treatment extremely induced SM -actin expression on RD 
cells. To explain increased SM -actin expression, other transcriptional factor would need to be 
explored (Figure 18). The transcriptional activation of the SM -actin gene is known to involve 
distinct transcriptional control mechanisms in different cell types and developmental stages. MCAT 
elements within promoter region is one of possible molecular basis for differential expression of 
SM -actin, since transcriptional enhancer factor-1 (TEF-1) family members show distinct binding 
patterns to MCAT among the cell types (Gan et al., 2007). TEF-1 and C/EBPβ transcriptional 
activities are regulated by p38 MAP kinase (Ambrosino et al., 2006） and TNF activates p38 
MAP kinase (Zhou et al., 2006）. Tissue-specific expression of SM -actin is required for the 
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principal force-generating capacity of the vascular smooth muscle cells. The SM -actin gene is 
also well known to be activated in cardiac primordium, switched off at later stage, and replaced by 
cardiac and skeletal -actins. In RD cells, the type of transcriptional factor involved in the 
modulation of SM -actin expression and transdifferentiation from a skeletal to smooth muscle 
lineage via LTR is still unclear at this moment. The application of knock-down experiment with 
siRNAs for representative transcriptional factors might be effective in addressing this point. 
Some groups have reported that LIGHT induces apoptosis through LTR alone (Rooney et al., 
2000) or both LTR and HVEM/TR2 (Zhai et al., 1998) in human colorectal cancer cell line HT29. 
In this study, I examined growth inhibition activity of LIGHT on RD cells. LIGHT decreased the 
number of viable RD cells up to one-third and slightly increased resting cells at G0/G1 phase (Figure 
3). The complete growth inhibition and marked increment in sub G1 population by LIGHT 
treatment were not observed as typical characteristics of apoptotic cells. Therefore, the effect of 
LIGHT on RD cells seemed to involve a delay of cell proliferation rather than a cell death. Similar 
results were obtained by LT12 treatment on RD cells. Common receptor for LIGHT and LT12 
is LTR, so growth delay on RD cells by these ligands might be mediated through only LTR. 
These discrepancies between cell lines used might be attributable to cellular characteristics, such as 
expression levels receptors, sensitivity to ligands, and signal transduction machineries. 
RMS is the most common soft tissue sarcoma in childhood and adolescence. In spite of 
clinical efforts conducted in worldwide, outcomes for high risk patients of this disease have not 
been improved and survival rates of relapsed or metastatic patients remain extremely low (Pappo et 
al., 1999). Currently, there are 18 embryonal and 12 adult alveolar human RMS cell lines. They 
differ in their origins, karyotypes, histology, and methods of validation (Hinson et al., 2013). I 
examined additional RMS cell lines available, A673 and A204, to confirm whether LIGHT can also 
induce differentiation with growth delay, but significant effects were not observed in these cell lines. 
Since these cells lack expression of myogenin, MyoD, or desmin, they might not be RMS origin or 
loose myogenic potential through passaging in culture condition (Morton and Potter, 1998). The 
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other cell line TE671, which was originally thought to be a medulloblastoma line, was later shown 
to be a subclone of RD cells by cytogenetic analysis and DNA fingerprinting (Stratton et al., 1989). 
TE671 would be valuable to confirm the effect of LIGHT on RMS in addition to RD cells. The 
most important point of this study is to show efficiency of cytokines, LIGHT and LT12, for 
growth suppression and transdifferentiation of RMS cell for the first time. This finding is expected 
to be a significant base in exploring effective medication for RMS. 
In part II, I demonstrated the SARM profile of TSAA-291 in mouse model. TSAA-291 is a 
steroidal anti-androgen previously used to treat BPH in Japan. Subsequent analysis suggested to me 
that divergent tissue specificity of TSAA-291 and endogenous androgens may stem from difference 
in recruitment of cofactors, especially PIAS1, to AR. The result is consistent with the previous 
finding that TSAA-291 has anabolic effects on muscle while having limited effects on the prostate 
and seminal vesicles in immature castrated rats (Masuoka et al., 1979). Administration of S-40542, 
novel non-steroidal SARM with clinical benefit against BPH, also decreased weight of prostate in 
dose-dependent manner by repeated administration to BPH rat models (Nejishima et al., 2012). In 
my study, administration of TSAA-291 at 10 and 30 mg/kg significantly increased the weight of the 
levator ani muscle without increasing that of the prostate and the seminal vesicle in castrated mice. 
The result was consistent with that of S-40542 and demonstrated that TSAA-291 has SARM 
properties in mice (Figure 10). In addition to them, I also observed that the treatment of castrated 
male mice with TSAA-291 at 3 to 30 mg/kg exhibited tendency to induce sexual behavior (Figure 
11). In humans, plasma levels of TSAA-291 after weekly intramuscular administration at 400 
mg/kg for 12 weeks is approximately 100 nM (Prescribing Information). A cellular response in 
reporter and M2H assays was observed at 100 nM TSAA-291 (Figures 9, 14, and 15). Therefore, 
there seems to be no discrepancy in effective concentrations of TSAA-291 between clinical 
situations, mouse models, and cellular models. 
In reporter assays with COS-7 cells, TSAA-291 displayed partial agonist activity (Figure 9A). 
Similar results were obtained with 293T cells (data not shown). The maximum AR agonist activity 
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of TSAA-291 was comparable to that of DHT in skeletal muscle cells. On the other hand, it was 
approximately half of DHT in prostate cells (Figure 9B). These discrepancies in in vitro activities in 
the prostate and muscle primary cells may reflect the in vivo profile of TSAA-291, which increases 
the weight of the levator ani muscle without having a stimulatory effect on the prostate. Moreover, 
an appropriate balance between agonistic and antagonistic activities of compounds might be 
necessary in exerting SARM profiles in vivo. 
The authentic mechanism underlying tissue-specificity of SARM is still uncertain. I 
hypothesized that it might result from difference in conformational change of AR induced by 
SARM and endogenous androgens. Since profiling of cofactor recruitment one of feasible 
approaches to confirm the hypothesis, I initially conducted comprehensive M2H cofactor 
recruitment analysis using 293T cells. As a result, the recruitment pattern of 12 cofactors to AR was 
different between SARM and endogenous androgens (Figure 14). These data suggest that SARM 
and endogenous androgens may induce different conformational changes of AR to recruit different 
cofactors. Whole AR molecule has not been successfully crystallized, but direct evidence for the 
difference in conformation between SARM-bound AR and endogenous androgens-bound AR may 
be obtained through protein engineering approaches. The 12 cofactors displaying different 
recruitment profiles between TSAA-291 and endogenous androgens in this study were categorized 
as follows: PIAS family, post-translational modifications-related molecules, cell cycle regulating 
protein, cytoskeleton-related protein, and others. Among those12 cofactors, not only PIAS1, but 
also PIAS3, PIAS4, and SENP1exhibited different recruitment pattern depending on ligands (Figure 
14). Therefore, further M2H analysis using primary cells was conducted to identify key cofactor. 
Interestingly, recruitment of PIAS1 in the presence of 100 nM SARM or endogenous androgens 
were markedly different between prostate and muscle cells, but the other cofactors showed no 
considerable differences (Figure 15). Intracellular environment might have some effect on these 
cell-dependent discrepancies in cofactor recruitment. I confirmed that PIAS1 functioned as a 
coactivator of AR (Figure 17). AR transactivation induced by TSAA-291 was detected in reporter 
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assay with skeletal muscle cells and it was more potent than that of prostate cells. It may be due to 
intensive PIAS1 recruitment to AR in skeletal muscle cells in response to TSAA-291. Based on 
these results, I presumed that PIAS1 is the most important cofactors to discuss the tissue selectivity 
of SARM and it is intracellular environment factor responsible for the different sensitivity in 
prostate and skeletal muscle cells. The discovery regarding the involvement of PIAS1 in SARM 
tissue selectivity has biological significance and is very meaningful for development of novel 
therapeutic agents. 
PIAS family genes are reported to interact with the DNA-binding domain of AR (Moilanen et 
al., 1999) and regulate the transcriptional activity for AR (Gross et al., 2001). However, the effects 
of PIAS family proteins on AR-dependent transcription are controversial. PIAS1 functions as an 
AR coactivator in prostate cancer cells (Gross et al., 2001). In contrast, PIAS1 binds p300 and 
behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO 
status (Ledsaak et al., 2016). These inconsistencies may arise from distinct expression patterns of 
cellular factors implicated in the regulation of AR-dependent transcription. PIAS1 has the 
characteristics of a scaffold/matrix attachment region-binding protein (Bode et al., 2000; Kipp et al., 
2000). As a scaffold attachment factor, PIAS family proteins may control the modulatory functions 
of many proteins and mediate crosstalk between different signaling pathways. In addition to PIAS1, 
PIAS4 also exhibited the different recruitment pattern in the presence of TSAA-291 and 
endogenous androgens (Figure 14). It was reported that PIAS4 represses the transcriptional activity 
of the AR and inhibits AR by recruiting histone deacetylases, independent of its SUMO ligase 
activity (Gross et al., 2004). Further investigation would be required for detailed understanding of 
functional roles of PIAS1 or PIAS family proteins in tissue selectivity of SARM. 
Some groups showed that different ligands induce distinct AR and estrogen receptor (ER) 
conformations leading to their association with different coactivator peptides using combinatorial 
peptide-phage display (Chang et al., 1999; Chang and McDonnell, 2002) and they may support my 
hypothesis. The other SARMs, that are RTI-018 and RTI-001, had potency as agonist and changed 
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kinetics of transcriptional activation response. These SARM may cause structural change of AR to 
lead association of SARM-AR with coactivator peptides which is distinct from DHT-AR complex 
(Kazmin et al., 2006). These findings also support my hypothesis that conformational change of AR 
induced by SARM lead association and recruitment of different co-regulators. 
It was reported that orally active non-steroidal SARM inhibited growth of prostate and breast 
tumors (Narayanan et al., 2014; Chisamore et al., 2016). MK-4541, known as a novel SARM, 
exerts anti-androgenic activity in xenograft models of prostate cancer (Chisamore et al., 2016). 
Enobosarm (GTx-024) is the most advanced SARM in clinical development. In the Phase II clinical 
trial of GTx-024, the drug was demonstrated to exert anti-tumor activity in breast cancer patients, 
such as inhibition of interaction between epithelial and mesenchymal stem cells and subsequent 
invasion and metastasis (Narayanan et al., 2014). In this study, I did not examined whether 
TSAA-291 itself shows anti-tumor activity in in vitro and in vivo or not, but non-steroidal SARM 
synthesized exhibited in vitro growth inhibition activities in various cancer cell lines (data not 
shown). 
Structurally distinct classes of orally active non-steroidal SARMs which are currently under 
development are resistant to 5α-reduction or aromatization. The resistance to these enzymes may be 
the other possible mechanism for the tissue selectivity of SARM (Buijsman et al., 2005). The most 
potent androgen for the prostate is DHT, which is formed by the 5α-reduction of Ts, and it is the 
most abundant circulating androgen. Inhibition of 5α-reductase by finasteride, a 5α-reductase 
inhibitor, leads to shrinkage of prostate size without any effect on muscle or bone mass. The result 
indicates that lack of possible 5α-reduction in Ts may cause different response in the prostate from 
the muscle and the bone (Wright et al., 1999). The expression of 5α-reductase gene is high in the 
prostate and the skin but low in the bone and the muscle. This discrepancy can explain the 
significance of DHT in the prostate and Ts in the muscle and the bone. SARMs cannot interact with 
5α-reductase and this is considered to be a one of logical explanations for their tissue selectivity. A 
substantial portion of TSAA-291 was reported to be converted into 5-DHTSAA-291, a reduced 
 99 
 
form of TSAA-291, in the prostate (Sudo et al., 1981), but TSAA-291 would be dominant in 
skeletal muscle due to low expression of 5-reductase. A series of my data was aligned well with 
these findings. AR binding affinity of 5-DHTSAA-291 is high in compared with TSAA-291 but 
AR agonistic activity is lower than TSAA-291 in reporter assays. The metabolite did not showed 
both recruitment of PIAS1 in M2H assay and weight change in the prostate and the levator ani 
muscle of castrated mice (data not shown). 
Aromatase is another enzyme that plays a pivotal role in steroid metabolism. The enzyme 
converts Ts to estradiol, which is the most physiologically important form of estrogen. This 
enzymatic reaction is known to be crucial in several physiological and pathological processes. 
Aromatase is ubiquitously expressed throughout the male reproductive organ and it contributes to 
local conversion of Ts to estradiol for prostate growth (Matzkin and Soloway, 1992; Tsugaya et al., 
1996). Excess amount of estradiol increases size of the prostate to be incidence risk of prostate 
cancer. Therefore, Ts may increase the prostate size through conversion into both estradiol and 
DHT. Since SARM cannot be aromatized, all of its effects will be explained by AR binding but not 
metabolic conversion into active androgens/estrogens in prostate. 
The other possible mechanism for the tissue selectivity of SARM is tissue-specific expression 
of cofactors. Prostatic cells exhibited higher PIAS1 expression than skeletal muscle cells (Figure 
16A). Similar trend was obtained in the prostate and the skeletal muscle tissues (Figure 16B). The 
high expression of PIAS1, greater recruitment of PIAS1 to the AR, and its co-activation of AR 
induced by DHT in prostate cells might be able to explain prostate-oriented activity of DHT. On the 
other hand, expression level of COX5B in skeletal muscle was higher than that in prostate tissue 
(Figure 16B). In the skeletal muscle, difference in recruitment of COX5B to the AR was not 
detected between TSAA-291 and DHT at 100 nM. Cofactors such as COX5B might account for the 
agonist activity of the AR in skeletal muscle. I need to examine whether COX5B acts as a 
coactivator of AR or not in my reporter assay with 293T cells. The result can be support 
responsibility of COX5B in AR co-activation in the skeletal muscle (Figure 19). Additional studies, 
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such as exploration for mutation or amplification status of these cofactors in target organs, will 
support elucidation for more promising mechanisms for tissue selectivity of SARM. 
LHRH analogs are widely used in cancer treatment. The mechanism of action of these 
analogs is mainly based on the inhibition of pituitary and gonadal functions (Emons and Schally, 
1994; Schally, 1999). The decrease in circulating LH and FSH by administration of LHRH analogs 
and concomitant down regulation of gonadal receptors for LH and FSH inhibit testicular or ovarian 
function and reduce sex-steroid levels. This state is called “chemical castration" or medical 
castration”. In addition to the pituitary gland, LHRH receptor is expressed in the prostate, the breast, 
the uterus, the ovaries, as well as many tumors. The function of these tissues might also be 
influenced by inhibitory actions of LHRH analogs (Emons and Schally, 1994, Schally, 1999, 
Schally et al., 2001). So, therapies with LHRH analogs cause a variety of adverse effects, such as 
accelerated bone loss with an increased risk of skeletal fractures, loss of libido, sexual behavior, 
depression, heart attacks, cardiovascular disease, and hot flashes (Smith et al., 2001; Higano, 2003; 
Harle et al., 2006; Sharma and Muggia, 2013). My data suggest that TSAA-291 has anabolic effects 
on skeletal muscle with limited and less harmful androgenic effects on the prostate. Therefore, 
combination treatment with TSAA-291 and LHRH analogs might be one of feasible therapeutic 
options for sex hormone-dependent diseases. Taken together, I confirmed that TSAA-291 is SARM 
and revealed that greater AR activation via higher recruitment of PIAS1 and other cofactors, such as 
COX5B, to AR in response to SARM in skeletal muscle cells than in prostate cells lead to higher 
anabolic/androgenic ratio profile of SARM in vivo (Figure 19). 
My studies showed that the discovery and development of medicine which was focused on the 
signal transduction is very useful due to their diverse physiological responses. Confirmation of 
anti-tumor activity or application for hormone-related disease of SARM (TSAA-291) and 
development of functional modulators for LIGHT or its receptor could lead further to a novel, 
effective and safe therapeutic approach for various diseases including cancer. 
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Figures 
 
Figure 18. Summary of my study regarding LIGHT-mediated growth inhibition activity in 
cancer cells. LIGHT activates the transcriptional machinery necessary for transdifferentiation from 
a skeletal- to smooth-muscle lineage via LTR. In my studies, the activated NF-B play only a 
minor role in significant morphological change and growth delay by LIGHT or LT12 treatment 
on RD cells. Other transcriptional factors might be involved in the cellular response. 
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Figure 19. Summary of my study regarding the tissue selectivity of SARM. The higher 
expression of PIAS1, greater recruitment of PIAS1 to the AR and the effect as coactivator of AR 
induced by DHT in prostate cells might explain the prostate-oriented activity of DHT. In skeletal 
muscle, the higher expression of COX5B and similar recruitment of COX5B to the AR between 
TSAA-291 and DHT at 100nM might account for the agonist activity of the AR. To confirm the 
responsibility of COX5B in skeletal muscle, the further examination whether or not COX5B acts as 
a coactivator of the AR is required.  
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